

Report of the 11th Flow and Virtual Crossmatch Exchange

August 11, 2017

| | |
|-------|-------|
| Cells | 61-62 |
| Serum | 63-66 |

For the 11th Flow and Virtual Crossmatch Exchange, Serum (patient) MX-059 and virtual donor V1 from Flow Crossmatch Exchange 10 (February, 2017) were re-examined as serum 63 and cell 61. A comparison of virtual crossmatch (VXM) predictions (MX-059 vs. V1) against actual flow crossmatch (FXM) outcome (**serum 63 vs. cell 61**) are summarized in part 1

of this report. Part 2 summarizes the flow crossmatch results for 2 cells (**cell nos. 61 - 62**) against 4 sera (**serum nos. 63 - 66**), and examines the single antigen data for the 4 sera. Finally, in part 3, the virtual crossmatch predictions for 4 potential donors (V1 - V4) against 2 sera (serum 65 and serum 66) are examined.

Part 1

Actual Flow Cytometric Crossmatch vs. Virtual Crossmatch

A direct comparison of virtual crossmatch (VXM) predictions and actual FXM results for cell 61 (V1) against serum 63 (MX-059) are summarized in the tables below. Of the 20 labs reporting VXM predictions in exchange 10, 17 reported back actual T-cell FXM results and 16 reported back actual B-cell FXM results (Table 1a). For the T-cell crossmatch, 13 of the 18 labs predicting the VXM to be positive, reported the actual FXM as positive in

agreement with predictions (Table 1b). Among the remaining 5 labs, 3 did not report back results and 2 reported the FXM as negative, despite the presence of class I DSA (B18, Bw6). Two labs predicting the T-cell crossmatch to be negative in Exchange 10, reported the actual crossmatch as positive.

For the B-cell crossmatch, better agreement was observed among labs

Table 1a. Summary of Actual Flow crossmatch results vs. Virtual Crossmatch predictions - Direct comparison

| Exchange 011 | | | | | Exchange 010 | | | | |
|---|-----------|-------|----------------------------|----------------------------|--|-----------|-------|-------------------|-------------------|
| Actual Flow Crossmatch - Serum 63 vs. Cell 61 | | | | | Virtual Crossmatch - Patient MX-059 vs. Donor V1 | | | | |
| Cell no. | Serum no. | #Labs | T-cell Results | B-cell Results | Donor | Serum no. | #Labs | T-cell Prediction | B-cell Prediction |
| 61 | 63 | 20 | POS(15) NEG(2) NT(3) | POS(12) NEG(4) NT(4) | V1 | 59 | 20 | POS(18) NEG(2) | POS(11) NEG(9) |
| < 80% agreement | | | | | | | | | |

Table 1b. Direct comparison of Actual crossmatch results vs. Virtual crossmatch results

| | | T-cell Virtual XM (Exchange 10) | | | B-cell Virtual XM (Exchange 10) | | | |
|---------------------------------|---|------------------------------------|---|---|------------------------------------|---|---|---|
| | | + | - | Ø | + | - | Ø | |
| Actual Flow XM (Exchange 11) | + | 13 | 2 | 0 | + | 7 | 5 | 0 |
| | - | 2 | 0 | 0 | - | 3 | 1 | 0 |
| | Ø | 3 | 0 | 0 | Ø | 1 | 3 | 0 |

+ = positive

- = negative

Ø = uncertain/not typed

n = number of labs

for the actual B-cell crossmatch than for B-cell predictions. However, agreement was still less than 80% among labs for the FXM. Seven of the 11 labs predicting the crossmatch to be positive, reported the actual B-cell FXM as positive in agreement with predictions, while 5/9 labs predicting the crossmatch to be negative, reported the actual FXM as positive.

A side by side comparison of actual FXM crossmatch results with virtual predictions for individual labs is shown in Table 1c. In Exchange 10, anti-B18 reactivity was reported against donor V1, with median MFI = 7409.

Additional reactivity to Bw6 (9262) was also reported by several labs. In Exchange 11, ant-B18 (7924) and -Bw6 (9561) reactivity was reported once again, with more labs (n=8) reporting reactivity to Bw6 the second time around. No class II DSA were detected in either study. The variability observed in the virtual B-cell crossmatch and the actual B-cell flow crossmatch may be due to a combination of factors, such as, the absence of class II DSA and by the presence of Bw6 antibodies.

Table 1c. Individual Actual Flow crossmatch results vs. Virtual crossmatch results - Direct Comparison

| Exchange 011 | | | | | Exchange 010 | | | | |
|---|---------------|-----------------------|---------------|-------------------|--|---------------------------|---------------------------|---------------------------|--------------------|
| Actual Flow Crossmatch - Serum 63 vs. Cell 61 | | | | | Virtual Crossmatch - Patient MX-059 vs. Donor V1 | | | | |
| Center | T-Cell RESULT | Class I DSA(MFI) | B-Cell RESULT | Class II DSA(MFI) | Center | Virtual T-cell Prediction | Class I DSA (MFI) | Virtual B-cell Prediction | Class II DSA (MFI) |
| 23 | Positive | B18(7924), Bw6(8122) | Negative | No DSA | 23 | Positive | B18 (9245) Bw6 (9005) | Positive | None |
| 54 | Negative | B18(10515) | Positive | No DSA | 54 | Positive | B18 (9440) | Negative | None |
| 206 | Positive | B18(8065) | Positive | No DSA | 206 | Positive | B18 (8815) | Positive | None |
| 230 | Positive | Bw6(10182) | Positive | No DSA | 230 | Positive | B18 (7590) | Negative | None |
| 774 | Positive | B18(8064) | Positive | No DSA | 774 | Positive | B18 (7399) | Negative | None |
| 792 | Positive | B18(7168) | Positive | No DSA | 792 | Positive | B18 (7335) | Positive | None |
| 836 | NT | B18(8427), Bw6(19557) | NT | No DSA | 836 | Positive | B27 (9729) B18 (7992) | Positive | None |
| 1160 | Positive | B18(9298), Bw6(19173) | Positive | No DSA | 1160 | Positive | B18 (7175) | Positive | None |
| 1461 | NT | | NT | | 1461 | Positive | B18(2320) | Negative | None |
| 2400 | Positive | B18(7040) | Negative | No DSA | 2400 | Negative | B18 (7152) | Negative | None |
| 3224 | Positive | B18(9351) | Positive | No DSA | 3224 | Positive | B18 (10742) | Positive | None |
| 3753 | Positive | B18(4637), Bw6(6819) | Positive | No DSA | 3753 | Positive | B18 (6557) | Positive | None |
| 3966 | NT | | NT | | 3966 | Positive | B18 (9860), B27(10139) | Negative | None |
| 4661 | Positive | B18(1567) | Positive | No DSA | 4661 | Positive | B18 (1142) | Positive | None |
| 5219 | Positive | NT | Positive | NT | 5219 | Positive | B18 (2376) | Negative | None |
| 8001 | Positive | B18(9408), Bw6(19543) | Positive | No DSA | 8001 | Positive | B18 (9725) | Positive | None |
| 8050 | Positive | B18(7905), Bw6(8940) | Negative | No DSA | 8050 | Positive | B18 (8550) Bw6 (9518) | Positive | None |
| 8083 | Negative | B18(6423) | Negative | No DSA | 8083 | Positive | B18 (7409) | Positive | None |
| 8096 | Positive | No DSA | NT | No DSA | 8096 | Negative | None | Negative | None |
| 8103 | Positive | B18(1386), Bw6(5507) | Positive | No DSA | 8103 | Positive | B18 (1524) Bw6 (5917) | Negative | None |

Part 2

Flow Cytometric Crossmatch

Flow cytometric crossmatch results for cell 61 and cell 62 against sera sample nos. 63 - 66 are summarized in Table 2. Individual results for each

laboratory, along with reported class I and class II DSA for each sera, are listed in tables 4 - 11.

Cell 61. The genotype for this sample from a donor of mixed ethnicity (Black/Caucasian) is A*11:01-A*26:01-B*18:01:01G-B*27:05:02G-C*06:08-C*07:01:01G/DRB1*03:02-DRB1*13:01-DRB3*01:01:02G-DRB3*02:02:01G-DQB1*04:02-DQB1*06:03-DPB1*01:01-DPB1*03:01. Overall, good agreement (>80%) was achieved for the T-cell crossmatch for cell 61 against all 4 sera, with the crossmatches against serum 63, 65, and 66 being reported as positive and the crossmatch against serum 64 reported as negative. Less agreement was observed for the B-cell crossmatch, as only 1 was reported with good agreement (cell 61 vs. serum 65). Against serum 63, 14 labs reported the B-cell crossmatch as positive, while 5 reported it as negative. Against serum 64, 14/18 labs reported the crossmatch a negative, with 1 lab noting it as borderline negative. For the last crossmatch pair (cell 61 vs. serum 66), 15 labs reported the B-cell crossmatch as positive and 4 reported it as negative.

Cell 62. The genotype for this sample from a donor of Vietnamese descent is A*01:01-A*29:01-B*07:05:01G-B*57:01-C*06:02:01G-C*15:05:01G-DRB1*07:01-DRB1*14:05-DRB3*02:02:01G-DRB4*01:03-DQB1*03:03-DRB1*05:01:01G. For the T-cell crossmatch, good agreement (>80%) was achieved among labs for cell 62 against all 4 samples, as the crossmatch against serum 63, 65, and 66 were reported as positive and the crossmatch against serum 64 was reported as negative. The B-cell crossmatch for this cell against all 4 sera was reported as positive. Three of the crossmatch pairs (cell 62 vs. serum 64-66) were reported with >80% agreement. For the B-cell crossmatch against serum 63, agreement among labs was < 80%, as 15 labs reported the crossmatch as positive, while 4 reported it as negative. Among the 4 labs reporting the crossmatch as negative, 1 indicated the cells were pronase treated.

Table 2. Summary of Flow crossmatch results for Cell #061-#062 vs. Serum #063-#066

| Cell no. | Serum no. | #Labs | T-cell Results | B-cell Results | Cell no. | Serum no. | #Labs | T-cell Results | B-cell Results |
|-----------------|-----------|-------|--------------------------|-----------------------------------|----------|-----------|-------|-----------------------------------|-----------------------------------|
| 61 | 63 | 21 | POS(19) NEG(2) | POS(14) NEG(5) NT(2) | 62 | 63 | 21 | POS(20) NEG(1) | POS(15) NEG(4) NT(2) |
| | | | | NEG(14) POS(4) NT(3) | | | | | |
| 61 | 64 | 21 | NEG(19) POS(2) | POS(17) NEG(2) NT(2) | 62 | 64 | 21 | NEG(18) POS(3) | POS(17) NEG(2) NT(2) |
| | | | | | | | | | |
| 61 | 65 | 21 | POS(18) NEG(3) | POS(18) NEG(3) | 62 | 65 | 21 | POS(18) NEG(1) NT(2) | POS(18) NEG(1) NT(2) |
| | | | | | | | | | |
| 61 | 66 | 21 | POS(19) NEG(2) | POS(15) NEG(4) NT(2) | 62 | 66 | 21 | POS(20) NEG(1) | POS(16) NEG(3) NT(2) |
| | | | | | | | | | |
| < 80% consensus | | | | | | | | | |

Antibody Identification

Class I and class II Luminex single antigen results for serum samples 63 - 66 are summarized in Tables 12 - 15 and individual results for each

participating laboratory are listed in Tables 16 –23. Potential DSA reported are based on single antigen results reported by labs.

Serum 63 was previously examined as serum 59 (Exchange 10). In this present study, anti-B18 (7924) and -Bw6 (9561) reactivity was reported against cell 61 (donor V1 from Exchange 10). Interestingly, twice as many labs (n=8) reported reactivity to Bw6 in this present study, compared to Exchange 10. Against cell 62, only a single DSA was reported (B7), with median MFI = 8895. No class II DSA were reported against either cell, as this serum was reported as negative for class II antibodies.

For serum 64, no class I or class II DSA were reported against cell 61. Meanwhile against cell 62, only 4 out of 18 labs reported anti-B7 reactivity, as the median MFI value across the 4 labs was only 1094. For class II, multiple DSA of various strengths were reported against cell 62, with labs reporting anti-DR53 and -DR7 reactivity, with respective MFI = 4106 and 5765. DR14 reactivity (8829) was reported by 13 labs, with 1 lab reporting allele specific DRB1*14:02 (6186) reactivity. However, DR14 is not a DSA against cell 62, as further testing by supplemental bead showed DRB1*14:02 is not cross-reactive with DRB1*14:05, which cell 62 carries.

Flow crossmatch and Antibody identification - Conclusion:

For the **T-cell flow crossmatch**, good agreement (>80%) was achieved for all 8 crossmatch pairs. For serum 63 and serum 66, the presence of multiple or strong class I DSA against cells 61 and 62, resulted in good agreement among labs in the reporting of flow crossmatch results. However, for serum 65 against each cell, less agreement was observed, as weak anti-B27 (2843 ± 1321) reactivity was reported against cell 61 and weak anti-B57 (5384 ± 1951) reactivity was reported against cell 62. This suggests the sensitivity of the T-Flow crossmatch is variable when the DSA strength is weak.

For the **B-cell flow crossmatch**, good agreement was observed for only half of the crossmatch pairs. Among the 4 pairs that did not achieve good agreement, the crossmatches against cell 61 accounting for 3 of them. For serum 63 against cell 61, all 18 labs reported anti-B18 (7924) reactivity against cell 61. In addition, 8/18 also reported additional anti-Bw6 (12230)

Serum 65 was reported as positive for class I DSA against cell 61 and cell 62. Anti-B27 (3095) reactivity was reported against cell 61, with MFI = 3095. Against cell 62, labs reported anti-B57 (5574) reactivity. For class II, no DSA were reported against cell 61. Against cell 62, all 19 labs detected strong reactivity to DR53 (12509). Additional weak anti-DR14 reactivity (2792) was reported by 15 labs, with 1 lab reporting allele specific reactivity to DRB1*14:01 (2053). Further testing by supplemental single antigen bead showed DRB1*14:01 cross-reactivity with DRB1*14:05, suggesting the anti-DR14 reactivity in this sample is a DSA against cell 62.

For **serum 66**, strong anti-B27 (8642) and Cw7 (12144) reactivity was reported against cell 61. Additional weak reactivity to Cw6 (2309) and A11 (2143) was also reported by some labs. Against cell 62, strong reactivity to B7 (12374), along with weak anti-Cw15 (3442) and -Cw6 (2309) reactivity was reported by labs. For class II, several labs did not detect class II antibodies in this sample. Among the 5 who did, 2 reported weak anti-DP5 (1267) reactivity against cell 62.

reactivity. No class II DSA were detected. For serum 66 against cell 61, a similar pattern was observed, in which anti-B27 (8642), -Cw7 (12144), and -Cw6 (2309) reactivity was reported, while no class II DSA were present. For each of these 2 crossmatch pairs, it would seem the presence of multiple class I DSA would result in a positive B-cell crossmatch, however, this was not the case, as some labs reported the crossmatch for the 2 pairs as negative. For the 3rd crossmatch pair, (serum 64 vs. cell 61), 4/14 labs reported the B-cell crossmatch as positive, despite the absence of class I or class II DSA. The presence of non-HLA antibodies in serum 64 is suspected. Finally, for serum 63 against cell 62, 4/15 labs reported it as negative, as no class II DSA were detected, only a single class I DSA (B7) of moderate strength (MFI = 7994 ± 2804). This suggests the sensitivity of the B-cell crossmatch is variable when a single class I DSA of moderate strength (< 8000) is present and there is no class II DSA.

Part 3

Virtual Crossmatch Paper Challenge

Virtual crossmatch predictions for donor V1 - V4 against sera (patient) samples 65 and 66 are summarized in Table 3 and individual laboratory

predictions are listed in Tables 24 - 31. Fictional donor histories precede each patient-donor summary.

For the virtual **T-cell crossmatch**, good agreement (< 80%) was achieved for 6 out of 8 patient-donor pairs. In the case of the positive predictions, good agreement was achieved in the presence of moderate to strong DSA, with MFI values for peak class I DSA ranging from 7400 - 9000. For serum 65 vs. donor V3 and serum 66 vs. donor V2, all but 2 labs predicted the crossmatch to be negative in the absence of class I DSA. For the remaining crossmatch pairs (serum 65 vs. donor V2 and serum 66 vs. donor V3) no agreement was achieved. In the case of serum 65 vs. donor V2, 13 labs predicted the crossmatch to be positive, 5 predicted it to be negative, and 2 predicted borderline results. Weak anti-B44 (2518) reactivity was reported, along with anti-Bw4 (5740) reactivity. Finally for serum 66 vs. donor V3, 15 labs predicted the crossmatch to be positive as anti-Cw7 (12144) reactivity was reported. Five labs predicted the crossmatch to be negative, with 1 lab noting no class I DSA were present.

For the virtual **B-cell crossmatch**, good agreement was achieved for 5 out of 8 patient donor pairs. Among the 5 pairs, 3 (serum 65 vs. donors V1, V3 and V4) were predicted to be positive in complete agreement, as strong anti-DR53 (12509) reactivity was reported in each case. For serum 65 against donor V2, 16 labs predicted it to be positive, 2 predicted borderline results, and 1 predicted it to be negative, as weak class I DSA (B44) and weak to moderate class II DSA (DR1, DP2) were reported, with respective MFI = 2518, 2474, 8187. For serum 66 against donor V2, all but 1 lab predicted it to be negative, as the majority of labs did not detect either class I or class II DSA. Finally, for the crossmatch pairs in which no consensus was achieved (serum 66 against donors V1, V3, and V4), predictions were widely variable among labs. In each case, no class II DSA were detected, only class I DSA, with median MFI values ranging from 8600 to 1300.

Table 3. Summary of Virtual Crossmatch Exchange #011 results (Serum #059-#60 versus Donor V1 - V4)

| Donor no. | Serum no. | #Labs | T-cell Prediction | B-cell Prediction | Predicted Risk Assessment | | Donor no. | Serum no. | #Labs | T-cell Prediction | B-cell Prediction | Predicted Risk Assessment |
|-----------|-----------|-------|---|-------------------|-----------------------------------|--|-----------|-----------|-------|---|---|---|
| V1 | 65 | 21 | POS(15) NEG(3) Borderline(2) NP(1) | POS(21) | Acceptable(1) Unacceptable(20) | | V2 | 65 | 20 | POS(13) NEG(5) Borderline(2) NP(1) | POS(16) NEG(1) Borderline(2) NP(1) | Acceptable(3) Unacceptable(16) Other(1) |
| | | | POS(18) NEG(1) Borderline(1) NP(1) | | | | | | | POS(2) NEG(17) Borderline(1) | POS(1) NEG(19) | Acceptable(18) Unacceptable(2) |
| V1 | 66 | 21 | POS(15) NEG(5) | POS(8) NEG(12) | Acceptable(5) Unacceptable(15) | | V2 | 66 | 20 | | | |

| Donor no. | Serum no. | #Labs | T-cell Prediction | B-cell Prediction | Predicted Risk Assessment | | Donor no. | Serum no. | #Labs | T-cell Prediction | B-cell Prediction | Predicted Risk Assessment |
|-----------|-----------|-------|----------------------------|-------------------|------------------------------------|--|-----------|-----------|-------|--------------------------|-------------------|------------------------------------|
| V3 | 65 | 20 | POS(2) NEG(17) NP(1) | POS(20) | Acceptable(2) Unacceptable(18) | | V4 | 65 | 20 | POS(19) Borderline(1) | POS(20) | Acceptable(1) Unacceptable(19) |
| | | | | | | | | | | | | |
| V3 | 66 | 20 | POS(10) NEG(10) | POS(20) | Acceptable(10) Unacceptable(20) | | V4 | 66 | 20 | POS(10) NEG(10) | POS(20) | Acceptable(10) Unacceptable(20) |

<80% agreement

NP = not predicted

Overall, good agreement was achieved in virtual crossmatch predictions in the presence of strong class I and class II DSA (MFI > 10,000), as well as in the presence of multiple DSA of moderate strength. In turn, when antibody strength was weak (< 5000) greater variability was observed among labs with respect to virtual crossmatch predictions. Interestingly, variability was also observed among lab predictions when the DSA reported was at the C- or DP-locus even when DSA strength was strong > 10,000, suggesting the variability observed in the virtual crossmatch is influenced by many factors, not just simply antibody strength.

Predicted renal transplant risk assessments were reported by all labs submitting virtual predictions. Seven out of 8 assessments were reported with good agreement among labs. Predicted risk was reported as unac-

ceptable when T-cell and or B-cell predictions were reported as positive. However, when T-cell predictions were variable among labs, variability in predicted risk assessments was also observed. For serum 66 against donor V3, 15 labs assessed the risk as unacceptable, while 5 assessed it to be acceptable in line with T-cell predictions.

A number of labs (n=16) reported cPRA values (Calculated Panel Reactive Antibodies), for the sera tested. The mean cPRA value for serum 65 was 94%, as this serum was positive for class I and class II antibodies. However, for serum 66, the mean cPRA was only 79%, as most labs did not detect class II antibodies in this serum, only class I. Among those that did report class II antibodies, 5 reported weak anti-DPW1 reactivity and 4 reported weak anti-DR18 reactivity, with respective MFI = 1229 and 1226.

Patient 1 (Serum 65):

History: This individual is a 50 year old male being evaluated for his second transplant. The HLA type of the patient is A11-A34-B62-B75-Cw4/DR15-DR51-DQ5-DQ6-DP5. The HLA typing of his first transplant is A11-A34-B62-Cw4-Cw7/DR11-DR15-DR51-DQ5-DQ6-DP1-DP5.

Against **donor V1**, anti-A24 (7142) reactivity of moderate strength was reported by all labs, with 2 labs also reporting allele level A*24:03 (3605) reactivity. Class II DSA detected were DR53 (12509), DP4 (DP401) (5314), and DR9 (2440). Virtual T-cell predictions were mixed among labs, with 15 labs predicting the crossmatch to be positive, 2 predicting borderline results, and 3 predicting it to be negative. By contrast, B-cell predictions were reported in complete agreement as positive. Predicted renal transplant risk was reported as unacceptable by all but 1 lab.

Weak anti-B44 (2518) reactivity was reported against **donor V2**. In addition, a number of labs (n=6) also reported reactivity to Bw4 (5740). For class II, anti-DP2 (8187) and -DR1 (2474) reactivity was reported. T-cell predictions were mixed among labs, with 13 labs predicting the crossmatch to be positive, 2 predicting it to be borderline, and 5 predicting it to be negative. Better agreement was achieved for B-cell predictions, as 16 labs predicted it to be positive, 2 predicted borderline results, and 1 predicted it to be negative. For predicted renal transplant risk, 16 labs assessed the risk as acceptable. Three assessed it as acceptable and 1 noted it would communicate with the clinical program.

There were only 3 labs reporting class I DSA against **donor V3**, with each reporting very weak anti-A68 (564) reactivity. By contrast, strong class II DSA (DR4, DR53, and DP4 (DP402) were reported against donor V3, with respective MFI = 17689, 12509, and 7687. For the virtual T-cell crossmatch, good agreement was achieved, as 17/19 labs predicted it to be positive. Good agreement was also achieved for the virtual B-cell crossmatch, as it was reported as positive in complete agreement. In turn, predicted renal transplant risk was reported as unacceptable by all but 2 labs.

Against **donor V4**, multiple class I and class II DSA were detected, as labs reported anti-B27 (3095), -B51(4916), -Bw4 (5740), and -DR53 (12509) reactivity. Additional weak reactivity to DP11 (1910) and DR7 (825) was reported by some labs. The presence of multiple DSA resulted in good agreement among labs with respect to predictions, as 19/20 labs predicted the T-cell crossmatch to be positive and 20/20 labs predicted the B-cell crossmatch to be positive. One lab predicted the T-cell crossmatch to be borderline. For rental transplant risk, all but 1 lab assessed the risk as unacceptable.

Patient 2 (Serum 66):

History: This individual is a 24 year old male being evaluated for his first transplant. The HLA type of the patient is A24-A33-B75-B58-Cw3-Cw4/DR9-DR12-DR52-DR53-DQ7-DQ9-DP5.

Against donor **V1**, multiple class I DSA (B56, Cw1, Cw7) were detected, with respective MFI values = 9816, 2897, and 12144. No class II DSA were reported against this donor. Good agreement was achieved among labs for the virtual T-cell crossmatch, as 18/20 labs reported it as positive. B-cell predictions were much more variable, with 10 labs predicting the crossmatch to be positive, 10 predicting it to be negative, and 1 predicting borderline results. Predicted renal transplant risk was reported as unacceptable by 18 labs and as acceptable by 2 labs.

With exception of a few labs reporting weak Cw5 (1021) and DP5 (1267) reactivity against **donor V2**, the remainder of the labs reported no class I or class II DSA were present against this donor. For the virtual T-cell crossmatch, good agreement was achieved as 17 labs predicted it to be negative, 1 predicted borderline results, and 2 predicted it to be positive. Good agreement was also achieved for B-cell predictions, as all but 1 lab predicted the B-cell crossmatch to be negative. Predicted renal transplant risk was reported as unacceptable by 18 labs and unacceptable by the 2 labs predicting the T-cell crossmatch to be positive.

Against **donor V3**, anti-Cw7 (12144) reactivity was reported by 17 labs. Three labs reported no class I DSA were present. Among them, 1 lab noted it detected Cw7 by single antigen (SAB), however by phenotype beads it was negative, and therefore a false positive by SAB assays. T-cell predictions were mixed among labs, as 15 labs predicted the T-cell crossmatch to be positive and 5 predicted it to be negative. B-cell predictions were also mixed among labs, as 8 labs predicted the B-cell crossmatch to be positive and 12 predicted it to be negative. Consequently, predicted renal transplant risk assessments were mixed, with 5 labs noting the risk as acceptable and 15 noting it as unacceptable in line with T-cell predictions.

Multiple class I DSA were reported against **donor V4**, with labs reporting ant-B27 (8242), -A3 (4263), -Cw1 (2897), and -Cw15 (3442) reactivity. No class II DSA were detected against the donor. T-cell predictions were reported in complete consensus as positive. B-cell predictions, however, were much more variable in the absence of class II DSA, with half (n=10) the labs predicting a positive crossmatch and the other half predicting a negative one. Predicted renal transplant risk for serum 66 against donor V4 was reported as unacceptable by all 20 labs.

NEXT MAILING DATE: March 28, 2018

Arlene Locke, David Gjertson, Qiuheheng Zhang, and Elaine F. Reed

Flow Crossmatch Results

Cell #061 - HLA genotype type: A*11:01-A*26:01-B*18:01:01G-B*27:05:02G-C*06:08-C*07:01:01G/ DRB1*03:02-DRB1*13:01-DRB3*01:01:02G-DRB3*02:02:01G-DQB1*04:02-DQB1*06:03-DPB1*01:01- DPB1*03:01

Table 4. Individual Flow crossmatch results and DSA reported for Cell #061 vs. Serum #063

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------------|----------------------------|-------------------|------------|-------|------|---------------|-----------------------------|-----------------------|-----------------------|-----------------|
| 23 | 63 | 10 | 171 | | | Positive | B18(7924), Bw6(8122) | 40 | 23 | | | Negative | No DSA | 573 | 796 | NO |
| 54 | 63 | | | | | Negative | B18(10515) | | | | | Positive | No DSA | | | NO |
| 206 | 63 | 2.98 | 41.57 | 6.67 | | Positive | B18(8065) | 4.94 | 74.4 | 6.7 | | Positive | No DSA | 7.34 | 13.05 | YES |
| 230 | 63 | 1 | 1.2 | | | Positive | Bw6(10182) | 2 | 21 | | | Positive | No DSA | 0.85 | 2.1 | NO |
| | | | | | | Positive No pronase | B18(9383) | | | | | Positive | | | | |
| 615 | 63 | 40 | 246 | | | | B18(9383) | 40 | 238 | | | Pronase | No DSA | 197 | 267 | YES |
| 774 | 63 | 50 | 154 | | | Positive | B18(8064) | 120 | 123 | | | Positive | No DSA | 258 | 333 | NO |
| 792 | 63 | 52 | 119 | | | Positive | B18(7168) | 106 | 116 | | | Positive | No DSA | 247 | 249 | YES |
| | | | | | | | | | | | | | | | | |
| 1160 | 63 | 90 | 210 | | | Positive | B18/Bw6(9298) | 120 | 207 | | | Positive | No DSA | 252 | 247 | YES |
| 2400 | 63 | 40 | 185 | | | Positive | B18(7040) | 80 | 6 | | | Negative | No DSA | 82 | 393 | NO |
| 3135 | 63 | 1,2 | 3311 | 1,2 | | Positive | NT | | | | | NT | NT | 2723 | | NO |
| 3224 | 63 | 70 | 77 | | | Positive | B18(9351) | 140 | 7 | | | Positive | No DSA | 255 | 239 | YES |
| 3625 | 63 | 40 LCS | 167 | N/A | N/A | Positive | B18(4718) | 40 LCS | 88 | N/A | N/A | Positive | No DSA | 157 | 304 | NO |
| | | | | | | | B18(4637), Bw6(6819) | | | | | | | | | |
| 3753 | 63 | 50 | 172 | | | Positive | Bw6(6819) | 100 | 156 | | | Positive | No DSA | 246 | 241 | YES |
| 4345 | 63 | | | | | Positive | NT | | | | | Negative | NT | | | NO |
| 4661 | 63 | 10 | 121 | | | Positive | B18(1567) | 10 | 130 | | | Positive | No DSA | 258 | 255 | YES |
| 5219 | 63 | 1 | | 4.87 | | Positive | NT | 1.2 | | 1.66 | | Positive | NT | 0.367 | 0.39 | NO |
| | | | | | | | | | | | | | | | | |
| 8001 | 63 | 50 | 181 | | | Positive | B18(9408), Bw6(19543) | 100 | 215 | | | Positive | No DSA | 289 | 270 | YES |
| 8050 | 63 | 50 | 171 | | 3551 | Positive | B18(7905), Bw6(8940) | 120 | 103 | | 4929 | Negative | No DSA | 97 | 195 | NO |
| 8083 | 63 | 90 | 40 | | | Negative | B18(6423) | 150 | 48 | | | Negative | No DSA | | | YES |
| 8096 | 63 | 20 | 42.13 | | | Positive | No DSA | NT | | | | NT | No DSA | 16.93 | NT | NO |
| 8103 | 63 | | 220 | | | Positive | B18(1386), Bw6(5507) | | | | | Positive | No DSA | 49.32 | 647.7 | NO |

Table 5. Individual Flow crossmatch results and DSA reported for Cell #061 vs. Serum #064

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------|----------------------------|-------------------|------------|-------|------|---------------|-----------------------------|-----------------------|-----------------------|-----------------|
| 23 | 64 | 10 | 2 | | | Negative | No DSA | 40 | 0 | | | Negative | No DSA | 573 | 796 | NO |
| 54 | 64 | | | | | Negative | No DSA | | | | | Negative | No DSA | | | NO |
| 206 | 64 | 2.98 | 3.27 | 1.45 | | Negative | No DSA | 4.94 | 15.6 | 2.2 | | Negative | No DSA | 7.34 | 13.05 | YES |
| 230 | 64 | 1 | 1 | | | Positive | No DSA | 2 | 0 | | | Negative | No DSA | 0.85 | 2.1 | NO |
| 615 | 64 | 40 | 37 | | | Negative | No DSA | 40 | | | | No result | No DSA | 197 | 267 | YES |
| 774 | 64 | 50 | 11 | | | Negative | No DSA | 120 | 28 | | | Negative | No DSA | 258 | 333 | NO |
| 792 | 64 | 52 | 14 | | | Negative | No DSA | 106 | 62 | | | Negative | DQ4(537) | 247 | 249 | YES |
| 1160 | 64 | 90 | <0 | | | Negative | No DSA | 120 | 108 | | | Borderline | DP1(788) DP3(865) | 252 | 247 | YES |
| 2400 | 64 | 40 | -13 | | | Negative | No DSA | 80 | -38 | | | Negative | No DSA | 82 | 393 | NO |
| 3135 | 64 | 1,2 | 2658 | 1,0 | | Negative | NT | | | | | NT | NT | 2723 | | NO |
| 3224 | 64 | 70 | | | | Negative | No DSA | 140 | | | | Negative | No DSA | 255 | 239 | YES |
| 3625 | 64 | 40 LCS | 25 | N/A | N/A | Negative | No DSA | 40 LCS | 51 | N/A | N/A | Positive | No DSA | 157 | 304 | NO |
| 3753 | 64 | 50 | 22 | | | Negative | No DSA | 100 | 72 | | | Negative | No DSA | 246 | 241 | YES |
| 4345 | 64 | | | | | Negative | NT | | | | | Negative | NT | | | NO |
| 4661 | 64 | 10 | 0 | | | Negative | No DSA | 10 | 37 | | | Positive | No DSA | 258 | 255 | YES |
| 5219 | 64 | 1 | | 1 | | Negative | NT | 1.2 | | 0.93 | | Negative | NT | 0.367 | 0.39 | NO |
| 8001 | 64 | 50 | 24 | | | Negative | No DSA | 100 | 140 | | | Positive | No DSA | 289 | 270 | YES |
| 8050 | 64 | 50 | 21 | | 689 | Negative | No DSA | 120 | 50 | | 2761 | Negative | No DSA | 97 | 195 | NO |
| 8083 | 64 | 90 | 29 | | | Negative | No DSA | 150 | 54 | | | Negative | No DSA | | | YES |
| 8096 | 64 | 20 | 12.25 | | | Negative | No DSA | NT | | | | NT | DR13(2001) | 16.93 | NT | NO |
| 8103 | 64 | | 102 | | | Positive | No DSA | | 2424 | | | Positive | No DSA | 49.32 | 647.7 | NO |

Table 6. Individual Flow crossmatch results and DSA reported for Cell #061 vs. Serum #065

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|------------------------|----------------------------|-------------------|------------|-------|-------|---------------|---------------------------------|-----------------------|-----------------------|-----------------|
| 23 | 65 | 10 | 67 | | | Positive | B27(3791) | 40 | 160 | | | Positive | DP3(5674) | 573 | 796 | NO |
| 54 | 65 | | | | | Negative | B27(4251) | | | | | Positive | DP3(9617) | | | NO |
| 206 | 65 | 2.98 | 13.77 | 2.88 | | Negative | B27(3146) | 4.94 | 130.45 | 11 | | Positive | No DSA | 7.34 | 13.05 | YES |
| 230 | 65 | 1 | 1.2 | | | Positive | No DSA | 2 | 20 | | | Positive | DP3(9130) | 0.85 | 2.1 | NO |
| 615 | 65 | 40 | 189 | | | Positive No pronase | B27(3095) | 40 | 363 | | | Positive | DP3(7252), DP1(1746) | 197 | 267 | YES |
| 774 | 65 | 50 | 66 | | | Positive | B27(2123) | 120 | 193 | | | Negative | DP3(7778) | 258 | 333 | NO |
| 792 | 65 | 52 | 60 | | | Positive | B27(3097) | 106 | 251 | | | Positive | DP3(7410), DQ4(1513), DP1(1256) | 247 | 249 | YES |
| 1160 | 65 | 90 | 117 | | | Positive | B27(3559) | 120 | 327 | | | Positive | DP3(8839) | 252 | 247 | YES |
| 2400 | 65 | 40 | 82 | | | Positive | B27(2293) | 80 | 75 | | | Negative | DP3(6164) | 82 | 393 | NO |
| 3135 | 65 | 1,2 | 3021 | 1,1 | | Negative | NT | | | | | NT | NT | 2723 | | NO |
| 3224 | 65 | 70 | | | | Borderline wk Positive | B27(3851) | 140 | 151 | | | Positive | DP3(9233) | 255 | 239 | YES |
| 3625 | 65 | 40 LCS | 92 | N/A | N/A | Positive | B27(1593) | 40 LCS | 182 | N/A | N/A | Positive | DP3(4662) | 157 | 304 | NO |
| 3753 | 65 | 50 | 109 | | | Positive | B27(2900) | 100 | 267 | | | Positive | DP3(4312) | 246 | 241 | YES |
| 4345 | 65 | | | | | Positive | NT | | | | | Positive | NT | | | NO |
| 4661 | 65 | 10 | 61 | | | Positive | B27(826) | 10 | 154 | | | Positive | DP3(656) | 258 | 255 | YES |
| 5219 | 65 | 1 | | 3.4 | | Positive | NT | 1.2 | | 4.89 | | Positive | NT | 0.367 | 0.39 | NO |
| 8001 | 65 | 50 | 104 | | | Positive | B27(3602) | 100 | 292 | | | Positive | DP3(8607), DQ4(1689), DP1(1758) | 289 | 270 | YES |
| 8050 | 65 | 50 | 96 | | 1564 | Positive | B27(2323) | 120 | 184 | | 11948 | Positive | DP3(7002) | 97 | 195 | NO |
| 8083 | 65 | 90 | 183 | | | Positive | B27(1364) | 150 | 328 | | | Positive | DP3(7211), DQ4(1614), DP1(1616) | | | YES |
| 8096 | 65 | 20 | 20.36 | | | Positive | B27(503) | NT | | | | NT | DQ4(1931) | 16.93 | NT | NO |
| 8103 | 65 | | 172 | | | Positive | No DSA | | 2880 | | | Positive | DP3(2894) | 49.32 | 647.7 | NO |

Table 7. Individual Flow crossmatch results and DSA reported for Cell #061 vs. Serum #066

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------------|-----------------------------------|-------------------|------------|-------|------|---------------|--------------------------------|-----------------------|-----------------------|-----------------|
| 23 | 66 | 10 | 250 | | | Positive | B27(7057), Cw7(9035), Cw6(1650) | 40 | 120 | | | Positive | DR18(1118) | 573 | 796 | NO |
| 54 | 66 | | | | | Positive | B27(5705), Cw7(9815), Cw6(1573) | | | | | Positive | No DSA | | | NO |
| 206 | 66 | 2.98 | 55.62 | 8.58 | | Positive | B27(9613) | 4.94 | 92.45 | 8.08 | | Positive | No DSA | 7.34 | 13.05 | YES |
| 230 | 66 | 1 | 1.3 | | | Positive | B27(12512), Cw7(17543), Cw6(3869) | 2 | 350 | | | Positive | No DSA | 0.85 | 2.1 | NO |
| 615 | 66 | 40 | 322 | | | Positive No pronase | B27(7688), Cw7(9472), Cw6(1829) | 40 | 339 | | | Positive | DP1(1350), DR18(1334) | 197 | 267 | YES |
| 774 | 66 | 50 | 171 | | | Positive | B27(10157), Cw7(12785) | 120 | 144.5 | | | Positive | No DSA | 258 | 333 | NO |
| 792 | 66 | 52 | 167 | | | Positive | B27(8234), Cw7(9672), Cw6(2078) | 106 | 161 | | | Positive | DP1(1078), DR18(488), DQ4(486) | 247 | 249 | YES |
| 1160 | 66 | 90 | 256 | | | Positive | B27(7810) | 120 | 257 | | | Positive | No DSA | 252 | 247 | YES |
| 2400 | 66 | 40 | 235 | | | Positive | B27(9053), Cw7(13236), Cw6(2309) | 80 | 28 | | | Negative | No DSA | 82 | 393 | NO |
| 3135 | 66 | 1,2 | 3984 | 1,5 | | Positive | NT | | | | | NT | NT | 2723 | | NO |
| 3224 | 66 | 70 | 137 | | | Positive | B27(8836), Cw7(9617), Cw6(1986) | 140 | 67 | | | Positive | No DSA | 255 | 239 | YES |
| 3625 | 66 | 40 LCS | 229 | N/A | N/A | Positive | B27(8164), Cw7(13257), Cw6(2278) | 40 LCS | 158 | N/A | N/A | Positive | No DSA | 157 | 304 | NO |
| 3753 | 66 | 50 | 218 | | | Positive | B27(7676), Cw7(14299), Cw6(3506) | 100 | 200 | | | Positive | No DSA | 246 | 241 | YES |
| 4345 | 66 | | | | | Positive | NT | | | | | Negative | NT | | | NO |
| 4661 | 66 | 10 | 165 | | | Positive | B27(2104), Cw7(1794) | 10 | 193 | | | Positive | No DSA | 258 | 255 | YES |
| 5219 | 66 | 1 | | 8.77 | | Positive | NT | 1.2 | | 11.1 | | Positive | NT | 0.367 | 0.39 | NO |
| 8001 | 66 | 50 | 205 | | | Positive | B27(10383), Cw7(12491), Cw6(2549) | 100 | 264 | | | Positive | DP1(1125) | 289 | 270 | YES |
| 8050 | 66 | 50 | 31 | | 768 | Negative | B27(9006), Cw7(14288), Cw6(2665) | 120 | 0 | | 936 | Negative | No DSA | 97 | 195 | NO |

Table 7. Individual Flow crossmatch results and DSA reported for Cell #061 vs. Serum #066

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------|-----------------------------------|-------------------|------------|-------|------|---------------|----------------------------------|-----------------------|-----------------------|-----------------|
| 8083 | 66 | 90 | 17 | | | Negative | B27(11475), Cw7(14719), Cw6(3739) | 150 | 22 | | | Negative | DP1(2526), DR18(1344), DQ4(1635) | | | YES |
| 8096 | 66 | 20 | 71.25 | | | Positive | B27(4301) | NT | | | | NT | No DSA | 16.93 | NT | NO |
| 8103 | 66 | | 179 | | | Positive | B27(2121), Cw7(3129) | | 1359 | | | Positive | No DSA | 49.32 | 647.7 | NO |

Cell #063 - HLA genotype:

A*01:01-A*29:01-B*07:05:01G-B*57:01-C*06:02:01G-C*15:05:01G/ DRB1*07:01-DRB1*14:05-DRB3*02:02:01G-DRB4*01:03-DQB1*03:03-DPB1*05:01:01G

Table 8. Individual Flow crossmatch results and DSA reported for Cell #062 vs. Serum #063

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control | B Cell NEG Control | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------------|----------------------------|-------------------|------------|-------|-------|---------------|-----------------------------|--------------------------------------|--------------------|-----------------|
| 23 | 63 | 10 | 252 | | | Positive | B7(9131) | 40 | 60 | | | Positive | No DSA | 557 | 837 | NO |
| 54 | 63 | | | | | Positive | B7(11836) | | | | | Positive | No DSA | | | YES |
| 206 | 63 | 2.98 | 37.57 | 6.71 | | Positive | B7(9303) | 4.94 | 44.95 | 5.45 | | Positive | No DSA | 6.58 | 10.1 | YES |
| 230 | 63 | 1 | 2.4 | | | Positive | No DSA | 2 | 5.7 | | | Positive | No DSA | 1 | 2.3 | NO |
| 615 | 63 | 50 | 331 | | | Positive No pronase | B7(9998) | 50 | 286 | | | Positive | No DSA | 189 | 288 | YES |
| | | | | | | | | | | | | | | 375 for 63, 64, 66; 314 for 65 | | |
| 774 | 63 | 50 | 172 | | | Positive | B7(8788) | 120 | 91 | | | Negative | No DSA | 222 | | NO |
| 792 | 63 | 52 | 152 | | | Positive | B7(8224) | 106 | 141 | | | Positive | No DSA | 248 | 279 | YES |
| 1160 | 63 | 90 | 267 | | | Positive | B7(10669) | 120 | 210 | | | Positive | No DSA | 239 | 315 | YES |
| 2400 | 63 | 40 | 237 | | | Positive | B7(8313) | 80 | 58 | | | Negative | No DSA | 38 | 355 | NO |
| 3135 | 63 | 1,2 | 5560 | 1,1 | | Negative | NT | | | | | NT | NT | 5258 | | NO |
| 3224 | 63 | 70 | 239 | | | Positive | B7(10846) | 140 | 132 | | | Positive | No DSA | 255 | 239 | YES |
| 3625 | 63 | 40 LCS | 170 | N/A | N/A | Positive | B7(5661) | 40 LCS | 83 | N/A | N/A | Positive | No DSA | 158 | 344 | NO |
| 3753 | 63 | 50 | 184 | | | Positive | B7(5497) | 100 | 190 | | | Positive | No DSA | 237 | 254 | YES |
| 4345 | 63 | | | | | Positive | NT | | | | | Negative | NT | | | NO |
| 4661 | 63 | 10 | 148 | | | Positive | B7(2458) | 10 | 171 | | | Positive | No DSA | 241 | 265 | YES |
| 5219 | 63 | 1 | | 8.66 | | Positive | NT | 1.2 | | 31.99 | | Positive | NT | 0.324 | 0.443 | NO |
| 8001 | 63 | 50 | 211 | | | Positive | B7(10298) | 100 | 264 | | | Positive | No DSA | 274 | 269 | YES |
| 8050 | 63 | 50 | 173 | | 4983 | Positive | B7(9001) | 120 | 165 | | 12080 | Positive | No DSA | 126 | 215 | NO |
| 8083 | 63 | 90 | 152 | | | Positive | B7(7588) | 150 | 84 | | | Negative | No DSA | | | YES |
| 8096 | 63 | 20 | 24.14 | | | Positive | B7(4358) | NT | | | | NT | No DSA | 14.88 | NT | NO |
| 8103 | 63 | | 152 | | | Positive | B7(1877) | | 2335 | | | Positive | No DSA | 53.52 | 1198.5 | NO |

Table 9. Individual Flow crossmatch results and DSA reported for Cell #062 vs. Serum #064

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------|----------------------------|-------------------|------------|-------|-------|---------------|-----------------------------------|-----------------------|--------------------------------|-----------------|
| 23 | 64 | 10 | 39 | | | Negative | No DSA | 40 | 139 | | | Positive | DR7(3909), DR53(2107) | 557 | 837 | NO |
| 54 | 64 | | | | | Negative | No DSA | | | | | Negative | DR7(6637), DR53(4845) | | | YES |
| 206 | 64 | 2.98 | 3.07 | 1.47 | | Negative | No DSA | 4.94 | 91.4 | 10.05 | | Positive | DR7(6213), DR53(4380) | 6.58 | 10.1 | YES |
| 230 | 64 | 1 | 0.85 | | | Negative | No DSA | 2 | 35 | | | Positive | DR7(6616), DR53(5180) | 1 | 2.3 | NO |
| 615 | 64 | 50 | 45 | | | Negative | No DSA | 50 | 329 | | | Positive | DR7(6188), DR53(4924) | 189 | 288 | YES |
| 774 | 64 | 50 | 34 | | | Negative | No DSA | 120 | 139 | | | Positive | DR7(5765), DR53(4327) | 222 | 375 for 63, 64, 66; 314 for 65 | NO |
| 792 | 64 | 52 | 22 | | | Negative | B7(986) | 106 | 206 | | | Positive | DR7(5292), DR53(4106) | 248 | 279 | YES |
| 1160 | 64 | 90 | 19 | | | Negative | No DSA | 120 | 272 | | | Positive | DR7(5490), DR14(7335), DR53(4022) | 239 | 315 | YES |
| 2400 | 64 | 40 | 11 | | | Negative | No DSA | 80 | 80 | | | Positive | DR7(4978), DR53(3276) | 38 | 355 | NO |
| 3135 | 64 | 1,2 | 3704 | 0,7 | | Negative | NT | | | | | NT | NT | 5258 | | NO |
| 3224 | 64 | 70 | 7 | | | Negative | No DSA | 140 | 193 | | | Positive | DR7(5772), DR53(3801) | 255 | 239 | YES |
| 3625 | 64 | 40 LCS | 19 | N/A | N/A | Negative | No DSA | 40 LCS | 152 | N/A | N/A | Positive | DR7(2462), DR53(1851) | 158 | 344 | NO |
| 3753 | 64 | 50 | 23 | | | Negative | No DSA | 100 | 220 | | | Positive | DR7(6883), DR53(4081) | 237 | 254 | YES |
| 4345 | 64 | | | | | Negative | NT | | | | | Positive | NT | | | NO |
| 4661 | 64 | 10 | 0 | | | Negative | No DSA | 10 | 123 | | | Positive | DR7(1794), DR53(1080) | 241 | 265 | YES |
| 5219 | 64 | 1 | | 1.06 | | WK Positive | NT | 1.2 | | 5.01 | | Positive | NT | 0.324 | 0.443 | NO |
| 8001 | 64 | 50 | 26 | | | Negative | B7(1143) | 100 | 308 | | | Positive | DR7(5937), DR53(4822) | 274 | 269 | YES |
| 8050 | 64 | 50 | 1 | | 760 | Negative | No DSA | 120 | 193 | | 16406 | Positive | DR7(6691), DR53(4416) | 126 | 215 | NO |

Table 9. Individual Flow crossmatch results and DSA reported for Cell #062 vs. Serum #064

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------|----------------------------|-------------------|------------|-------|------|---------------|-----------------------------|-----------------------|-----------------------|-----------------|
| 8083 | 64 | 90 | 151 | | | Positive | B7(1164), A1(1120) | 150 | 136 | | | Negative | DR7(3108), DR53(2693) | | | YES |
| 8096 | 64 | 20 | 7.63 | | | Negative | No DSA | NT | | | | NT | DR7(4872), DR53(4685) | 14.88 | NT | NO |
| 8103 | 64 | | 109 | | | Positive | No DSA | | 3715 | | | Positive | DR7(1285), DR53(840) | 53.52 | 1198.5 | NO |

Table 10. Individual Flow crossmatch results and DSA reported for Cell #062 vs. Serum #065

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------------|----------------------------|-------------------|------------|-------|-------|---------------|------------------------------------|-----------------------|--------------------------------|-----------------|
| 23 | 65 | 10 | 171 | | | Positive | B57(6352) | 40 | 132 | | | Positive | DR53(5950), DR14(992) | 557 | 837 | NO |
| 54 | 65 | | | | | Negative | B57(8435) | | | | | Negative | DR53(15781), DR14(3497), DQ9(2117) | | | YES |
| 206 | 65 | 2.98 | 19.02 | 3.89 | | Positive | B57(6368) | 4.94 | 58.75 | 6.82 | | Positive | DR53(14179), DR14(3330) | 6.58 | 10.1 | YES |
| 230 | 65 | 1 | 2.1 | | | Positive | B57(7524) | 2 | 10 | | | Positive | DR53(15668), DR14(3293) | 1 | 2.3 | NO |
| 615 | 65 | 50 | 278 | | | Positive No pronase | B57(5809) | 50 | 365 | | | Positive | DR53(11802), DR14(2792), DQ9(1706) | 189 | 288 | YES |
| 774 | 65 | 50 | 100 | | | Positive | B57(5346) | 120 | 173 | | | Positive | DR53(13875), DR14(2688) | 222 | 375 for 63, 64, 66; 314 for 65 | NO |
| 792 | 65 | 52 | 104 | | | Positive | B57(5497) | 106 | 200 | | | Positive | DR53(12004), DR14(2794), DQ9(1857) | 248 | 279 | YES |
| 1160 | 65 | 90 | 199 | | | Positive | B57(6337) | 120 | 276 | | | Positive | DR53(13027), DR14(2272), DQ9(1106) | 239 | 315 | YES |
| 2400 | 65 | 40 | 155 | | | Positive | B57(5481) | 80 | 92 | | | Positive | DR53(11465), DR14(2285) | 38 | 355 | NO |
| 3135 | 65 | 1,2 | 4546 | 0,9 | | Negative | NT | | | | | NT | NT | 5258 | | NO |
| 3224 | 65 | 70 | 167 | | | Positive | B57(7424) | 140 | 177 | | | Positive | DR53(13139), DR14(3438), DQ9(2150) | 255 | 239 | YES |
| 3625 | 65 | 40 LCS | 91 | N/A | N/A | Positive | B57(3469) | 40 LCS | 109 | N/A | N/A | Positive | DR53(7295), DR14(1310) | 158 | 344 | NO |
| 3753 | 65 | 50 | 147 | | | Positive | B57(5651) | 100 | 211 | | | Positive | DR53(10896) | 237 | 254 | YES |
| 4345 | 65 | | | | | Positive | NT | | | | | Positive | NT | | | NO |
| 4661 | 65 | 10 | 125 | | | Positive | B57(1554) | 10 | 169 | | | Positive | DR53(862) | 241 | 265 | YES |
| 5219 | 65 | 1 | | 7.3 | | Positive | NT | 1.2 | | 13.71 | | Positive | NT | 0.324 | 0.443 | NO |
| 8001 | 65 | 50 | 164 | | | Positive | B57(6855) | 100 | 311 | | | Positive | DR53(14406), DR14(3057), DQ9(2003) | 274 | 269 | YES |
| 8050 | 65 | 50 | 115 | | 2643 | Positive | B57(4892) | 120 | 188 | | 15533 | Positive | DR53(12760) | 126 | 215 | NO |
| 8083 | 65 | 90 | 230 | | | Positive | B57(2733) | 150 | 240 | | | Positive | DR53(12509), DR14(2715), DQ9(1827) | | | YES |
| 8096 | 65 | 20 | 18.18 | | | Negative | No DSA | NT | | | | NT | DR53(9269), DR14(2323) | 14.88 | NT | NO |
| 8103 | 65 | | 180 | | | Positive | B57(1134) | | 2601 | | | Positive | DR53(3339) | 53.52 | 1198.5 | NO |

Table 11. Individual Flow crossmatch results and DSA reported for Cell #062 vs. Serum #066

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------|----------------------------------|-------------------|------------|-------|-------|---------------|-----------------------------|-----------------------|--------------------------------|-----------------|
| 23 | 66 | 10 | 288 | | | Positive | B7(9505), Cw15(2518), Cw6(1650) | 40 | 101 | | | Positive | No DSA | 557 | 837 | NO |
| 54 | 66 | | | | | Positive | B7(9774), Cw15(3462), Cw6(1573) | | | | | Positive | No DSA | | | YES |
| 206 | 66 | 2.98 | 64.87 | 10.86 | | Positive | B7(12738) | 4.94 | 69.05 | 7.84 | | Positive | No DSA | 6.58 | 10.1 | YES |
| 230 | 66 | 1 | 0.7 | | | Negative | B7(18112), Cw15(5648), Cw6(3869) | 2 | 300 | | | Positive | No DSA | 1 | 2.3 | NO |
| 615 | 66 | 50 | 381 | | | Positive | B7(11086), Cw15(2660), Cw2(1829) | 50 | 347 | | | Positive | No DSA | 189 | 288 | YES |
| 774 | 66 | 50 | 209 | | | Positive | B7(12344) | 120 | 154 | | | Positive | No DSA | 222 | 375 for 63, 64, 66; 314 for 65 | NO |
| 792 | 66 | 52 | 197 | | | Positive | B7(10338), Cw15(3051), Cw6(2078) | 106 | 188 | | | Positive | DP5(680), DR53(355) | 248 | 279 | YES |
| 1160 | 66 | 90 | 313 | | | Positive | B7(11972), Cw15(2167) | 120 | 257 | | | Positive | No DSA | 239 | 315 | YES |
| 2400 | 66 | 40 | 277 | | | Positive | B7(12824), Cw15(3337), Cw6(2309) | 80 | 77 | | | Negative | No DSA | 38 | 355 | NO |
| 3135 | 66 | 1,2 | 7053 | 1,3 | | Positive | NT | | | | | NT | NT | 5258 | | NO |
| 3224 | 66 | 70 | 303 | | | Positive | B7(12404), Cw15(3078), Cw6(1986) | 140 | 190 | | | Positive | No DSA | 255 | 239 | YES |
| 3625 | 66 | 40 LCS | 204 | N/A | N/A | Positive | B7(11264), Cw15(3186), Cw6(2278) | 40 LCS | 136 | N/A | N/A | Positive | No DSA | 158 | 344 | NO |
| 3753 | 66 | 50 | 247 | | | Positive | B7(12745), Cw15(4647), Cw6(3506) | 100 | 247 | | | Positive | No DSA | 237 | 254 | YES |
| 4345 | 66 | | | | | Positive | NT | | | | | Negative | NT | | | NO |
| 4661 | 66 | 10 | 210 | | | Positive | B7(3590) | 10 | 234 | | | Positive | No DSA | 241 | 265 | YES |
| 5219 | 66 | 1 | | 11.66 | | Positive | NT | 1.2 | | 24.9 | | Positive | NT | 0.324 | 0.443 | NO |
| 8001 | 66 | 50 | 233 | | | Positive | B7(12981), Cw15(3669), Cw6(2549) | 100 | 314 | | | Positive | No DSA | 274 | 269 | YES |
| 8050 | 66 | 50 | 161 | | 4370 | Positive | B7(12703), Cw15(3442), Cw6(2665) | 120 | 175 | | 13475 | Positive | No DSA | 126 | 215 | NO |

Table 11. Individual Flow crossmatch results and DSA reported for Cell #062 vs. Serum #066

| Center | Serum no | T Cell Pos cutoff | T Cell MCS | RATIO | MESF | T-Cell RESULT | Potential Class I DSA(MFI) | B Cell Pos cutoff | B-cell MCS | RATIO | MESF | B-Cell RESULT | Potential Class II DSA(MFI) | T Cell NEG Control MC | B Cell NEG Control MC | Pronase Treated |
|--------|----------|-------------------|------------|-------|------|---------------|----------------------------------|-------------------|------------|-------|------|---------------|-----------------------------|-----------------------|-----------------------|-----------------|
| 8083 | 66 | 90 | 101 | | | Positive | B7(14120), Cw15(4767), Cw6(3739) | 150 | 35 | | | Negative | DP5(1853) | | | YES |
| 8096 | 66 | 20 | 34.4 | | | Positive | B7(5790), Cw15(3945) | NT | | | | NT | No DSA | 14.88 | NT | NO |
| 8103 | 66 | | 153 | | | Positive | B7C(3067) | | 1870 | | | Positive | No DSA | 53.52 | 1198.5 | NO |

Single Antigen Results

Table 12. Summary of Single Antigen results for Serum #063

| Class I *** Serum 63 *** 18 typing Labs | | | | | | | | |
|---|---------|-----------|--------|-------|---------|------|-------|--|
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| B44 | 18 | 100% | 14438 | 13204 | 4056 | 4323 | 18337 | |
| B45 | 18 | 100% | 18071 | 16131 | 4513 | 5227 | 20738 | |
| B7 | 18 | 100% | 8895 | 7994 | 2804 | 1877 | 11836 | |
| B18 | 17 | 94% | 7924 | 7134 | 2572 | 1386 | 10515 | |
| B35 | 17 | 94% | 7992 | 7173 | 2566 | 1571 | 10449 | |
| B42 | 17 | 94% | 9297 | 8293 | 3009 | 1821 | 12502 | |
| B55 | 17 | 94% | 6659 | 6240 | 2309 | 1557 | 9499 | |
| B56 | 17 | 94% | 8229 | 7307 | 2778 | 1552 | 11168 | |
| B60 | 17 | 94% | 6820 | 6420 | 2419 | 1451 | 9846 | |
| B62 | 17 | 94% | 7394 | 6595 | 2362 | 1615 | 9833 | |
| B67 | 17 | 94% | 10036 | 8727 | 3236 | 2116 | 13406 | |
| B71 | 17 | 94% | 7918 | 7008 | 2482 | 1625 | 10240 | |
| B72 | 17 | 94% | 7222 | 6644 | 2287 | 1539 | 9953 | |
| B75 | 17 | 94% | 7444 | 7107 | 2857 | 1569 | 11352 | |
| B76 | 17 | 94% | 16579 | 14460 | 4565 | 4590 | 19366 | |
| B8 | 17 | 94% | 8815 | 7727 | 2751 | 1758 | 11793 | |
| B41 | 16 | 88% | 8137 | 7408 | 2769 | 1406 | 11105 | |
| B50 | 16 | 88% | 8982 | 8154 | 2706 | 1901 | 11801 | |
| B54 | 16 | 88% | 7700 | 6955 | 2379 | 1667 | 9965 | |
| B61 | 16 | 88% | 7805 | 7147 | 2597 | 1431 | 10415 | |
| B64 | 16 | 88% | 6749 | 6155 | 2289 | 1481 | 9258 | |
| B48 | 15 | 83% | 6911 | 6531 | 2180 | 797 | 9295 | |
| B39 | 14 | 77% | 8289 | 7850 | 2481 | 1563 | 11490 | |
| B65 | 14 | 77% | 3908 | 3873 | 1256 | 869 | 5559 | |
| B82 | 12 | 66% | 13921 | 12535 | 3784 | 3808 | 17028 | |
| B52 | 11 | 61% | 1890 | 1756 | 404 | 716 | 2168 | |
| B78 | 11 | 61% | 6494 | 6168 | 1974 | 1322 | 8694 | |
| B81 | 11 | 61% | 8553 | 8125 | 2520 | 1810 | 11484 | |
| B2708 | 9 | 50% | 9900 | 8647 | 2971 | 2239 | 11357 | |
| B49 | 9 | 50% | 1660 | 1774 | 372 | 1214 | 2436 | |
| Bw6 | 8 | 50% | 9561 | 12230 | 5720 | 5507 | 19557 | |
| B27 | 8 | 44% | 8129 | 6938 | 3541 | 2239 | 12770 | |
| B7801 | 6 | 33% | 4824 | 4664 | 2612 | 1322 | 8113 | |
| B8101 | 6 | 33% | 5975 | 5806 | 3357 | 1524 | 10356 | |
| B3901 | 5 | 27% | 5287 | 5806 | 3689 | 1563 | 10515 | |
| B8201 | 5 | 27% | 13080 | 12160 | 3415 | 6730 | 15616 | |

| Class II *** Serum 63 *** 18 typing Labs | | | | | | | | |
|--|---------|-----------|--------|------|---------|-----|-----|--|
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| class II negative | | | | | | | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #56

Table 13. Summary of Single Antigen results Serum #064

| Class I | | | | | | | | |
|------------------|---------|-----------|--------|------|---------|------|------|--|
| *** Serum 64 *** | | | | | | | | |
| 18 typing Labs | | | | | | | | |
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| B8 | 18 | 100% | 5972 | 5456 | 2243 | 802 | 8838 | |
| A32 | 10 | 55% | 1748 | 1924 | 579 | 1327 | 3390 | |
| B42 | 6 | 33% | 1193 | 1294 | 241 | 1025 | 1648 | |
| B54 | 4 | 22% | 1087 | 1165 | 200 | 982 | 1504 | |
| B7 | 4 | 22% | 1114 | 1094 | 69 | 986 | 1164 | |
| Cw1 | 3 | 16% | 1679 | 1714 | 420 | 1218 | 2246 | |
| A1 | 2 | 11% | 890 | 890 | 230 | 660 | 1120 | |
| A80 | 2 | 11% | 902 | 901 | 538 | 364 | 1439 | |
| B59 | 2 | 11% | 1177 | 1177 | 249 | 928 | 1426 | |
| B76 | 2 | 11% | 1198 | 1198 | 153 | 1045 | 1351 | |
| B81 | 2 | 11% | 927 | 926 | 92 | 835 | 1018 | |
| Cw12 | 2 | 11% | 1628 | 1628 | 286 | 1342 | 1914 | |

| Class II | | | | | | | | |
|------------------|---------|-----------|--------|-------|---------|------|-------|--|
| *** Serum 64 *** | | | | | | | | |
| 19 typing Labs | | | | | | | | |
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| DR53 | 19 | 100% | 4106 | 3644 | 1268 | 840 | 5180 | |
| DR7 | 19 | 100% | 5765 | 5050 | 1676 | 1285 | 6883 | |
| DR1 | 18 | 94% | 13632 | 12331 | 4148 | 2491 | 17606 | |
| DR10 | 18 | 94% | 3383 | 2989 | 1087 | 662 | 4174 | |
| DR103 | 18 | 94% | 5661 | 5034 | 1926 | 980 | 7176 | |
| DR4 | 17 | 89% | 9610 | 8393 | 2933 | 2513 | 12174 | |
| DR51 | 17 | 89% | 6170 | 5246 | 1823 | 1275 | 7178 | |
| DR9 | 17 | 89% | 4307 | 3969 | 1462 | 1016 | 5899 | |
| DR14 | 13 | 68% | 8829 | 8246 | 1836 | 4451 | 10047 | |
| DR15 | 13 | 68% | 3515 | 3082 | 1280 | 562 | 4379 | |
| DQ2 | 5 | 26% | 1399 | 2026 | 1237 | 1321 | 4495 | |
| DP14 | 3 | 15% | 730 | 2063 | 1901 | 707 | 4752 | |
| DP17 | 3 | 15% | 799 | 1156 | 600 | 668 | 2001 | |
| DP10 | 2 | 10% | 716 | 715 | 37 | 679 | 752 | |
| DP11 | 2 | 10% | 823 | 823 | 16 | 807 | 839 | |
| DP13 | 2 | 10% | 692 | 692 | 23 | 669 | 715 | |
| DP19 | 2 | 10% | 781 | 781 | 101 | 680 | 882 | |
| DP20 | 2 | 10% | 692 | 691 | 8 | 684 | 699 | |
| DP9 | 2 | 10% | 758 | 758 | 18 | 740 | 776 | |
| DPw1 | 2 | 10% | 779 | 779 | 9 | 770 | 788 | |
| DPw3 | 2 | 10% | 845 | 844 | 21 | 824 | 865 | |
| DPw5 | 2 | 10% | 813 | 812 | 9 | 804 | 821 | |
| DPw6 | 2 | 10% | 762 | 761 | 8 | 754 | 769 | |
| DQA1*05 | 2 | 10% | 1340 | 1339 | 19 | 1321 | 1358 | |
| DP26 | 1 | 5% | 1055 | 1055 | - | 1055 | 1055 | |
| DPA1*02 | 1 | 5% | 1048 | 1048 | - | 1048 | 1048 | |
| DPA1*03 | 1 | 5% | 1055 | 1055 | - | 1055 | 1055 | |
| DQA1*02 | 1 | 5% | 1077 | 1077 | - | 1077 | 1077 | |
| DR13 | 1 | 5% | 2001 | 2001 | - | 2001 | 2001 | |
| DR16 | 1 | 5% | 6086 | 6086 | - | 6086 | 6086 | |

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #56

Table 14. Summary of Single Antigen results Serum #065

| Class I | | | | | | | | |
|------------------|---------|-----------|--------|------|---------|------|-------|--|
| *** Serum 65 *** | | | | | | | | |
| 19 typing Labs | | | | | | | | |
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| A23 | 18 | 95% | 7475 | 6798 | 3051 | 551 | 10941 | |
| A24 | 18 | 95% | 7142 | 6509 | 3056 | 494 | 10913 | |
| A25 | 18 | 95% | 5265 | 4839 | 2247 | 353 | 8306 | |
| A32 | 18 | 95% | 6157 | 5547 | 2451 | 654 | 9099 | |
| B57 | 18 | 95% | 5574 | 5384 | 1951 | 1134 | 8435 | |
| B27 | 17 | 89% | 3095 | 2843 | 1321 | 503 | 6016 | |
| B49 | 17 | 89% | 4785 | 4185 | 1911 | 544 | 7054 | |
| B58 | 17 | 89% | 5308 | 5104 | 1973 | 969 | 7952 | |
| B59 | 17 | 89% | 3738 | 3252 | 1418 | 501 | 5124 | |
| B38 | 16 | 84% | 5034 | 4565 | 1806 | 1027 | 7098 | |
| B44 | 16 | 84% | 2518 | 2518 | 1174 | 531 | 4581 | |
| B53 | 16 | 84% | 4657 | 4185 | 1557 | 1022 | 6174 | |
| B63 | 16 | 84% | 5081 | 4730 | 2015 | 1166 | 8880 | |
| B77 | 16 | 84% | 3942 | 3615 | 1370 | 870 | 5642 | |
| B51 | 15 | 79% | 4916 | 4650 | 1572 | 599 | 6746 | |
| B52 | 15 | 79% | 3858 | 3598 | 1195 | 670 | 5342 | |
| B37 | 14 | 74% | 3008 | 2748 | 931 | 598 | 3947 | |
| B13 | 12 | 63% | 2516 | 2382 | 1025 | 318 | 3925 | |
| A80 | 11 | 58% | 1780 | 1754 | 566 | 406 | 2789 | |
| B47 | 10 | 53% | 1893 | 1815 | 583 | 490 | 2577 | |
| Bw4 | 7 | 37% | 5740 | 5219 | 1947 | 1827 | 7424 | |
| A2 | 6 | 32% | 1229 | 1198 | 206 | 885 | 1451 | |
| A2403 | 5 | 26% | 3605 | 4483 | 2835 | 1545 | 8769 | |
| B76 | 4 | 21% | 1135 | 1284 | 298 | 1069 | 1798 | |
| A68 | 2 | 11% | 564 | 564 | 49 | 515 | 613 | |
| A69 | 2 | 11% | 709 | 709 | 36 | 673 | 745 | |
| A210 | 1 | 5% | 1202 | 1202 | - | 1202 | 1202 | |
| B15 | 1 | 5% | 1166 | 1166 | - | 1166 | 1166 | |

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #56

| Class II | | | | | | | | |
|------------------|---------|-----------|--------|-------|---------|-------|-------|--|
| *** Serum 65 *** | | | | | | | | |
| 19 typing Labs | | | | | | | | |
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| DR53 | 19 | 100% | 12509 | 11186 | 4004 | 862 | 15781 | |
| DR11 | 18 | 94% | 4796 | 4430 | 1624 | 457 | 7965 | |
| DR4 | 18 | 94% | 17689 | 15871 | 4315 | 3464 | 20032 | |
| DPw3 | 17 | 89% | 7252 | 6739 | 2371 | 656 | 9617 | |
| DP14 | 16 | 84% | 5911 | 5392 | 1985 | 450 | 7983 | |
| DP17 | 16 | 84% | 5953 | 5192 | 1899 | 454 | 7788 | |
| DP18 | 16 | 84% | 7244 | 6563 | 2370 | 669 | 9686 | |
| DP28 | 16 | 84% | 7104 | 6448 | 2496 | 545 | 9321 | |
| DP9 | 16 | 84% | 6295 | 5674 | 2039 | 496 | 7885 | |
| DPw2 | 16 | 84% | 8187 | 7444 | 2536 | 799 | 10723 | |
| DPw6 | 16 | 84% | 6126 | 5437 | 1835 | 628 | 7620 | |
| DR10 | 15 | 78% | 3365 | 3132 | 724 | 1935 | 4402 | |
| DR14 | 15 | 78% | 2792 | 2668 | 716 | 992 | 3497 | |
| DP10 | 14 | 73% | 6152 | 5836 | 1194 | 3526 | 7413 | |
| DP20 | 14 | 73% | 7310 | 7160 | 1362 | 4196 | 9166 | |
| DR1 | 12 | 63% | 2474 | 2378 | 874 | 1261 | 4592 | |
| DR9 | 12 | 63% | 2440 | 2513 | 532 | 1729 | 3657 | |
| DP402 | 10 | 52% | 7037 | 6722 | 2865 | 880 | 10097 | |
| DQ8 | 9 | 47% | 2311 | 3508 | 3354 | 1955 | 12980 | |
| DPw4 | 8 | 42% | 8337 | 8195 | 2124 | 3306 | 10912 | |
| DQ7 | 8 | 42% | 1698 | 1690 | 283 | 1085 | 2079 | |
| DQ9 | 8 | 42% | 1996 | 1987 | 171 | 1706 | 2248 | |
| DP11 | 6 | 31% | 1910 | 1922 | 169 | 1659 | 2138 | |
| DP19 | 6 | 31% | 1987 | 1844 | 293 | 1313 | 2109 | |
| DP23 | 5 | 26% | 1393 | 1398 | 154 | 1152 | 1628 | |
| DPw1 | 5 | 26% | 1706 | 1616 | 187 | 1256 | 1758 | |
| DQ4 | 5 | 26% | 1614 | 1620 | 82 | 1513 | 1733 | |
| DP13 | 4 | 21% | 1376 | 1333 | 148 | 1092 | 1491 | |
| DP401 | 3 | 15% | 2291 | 1956 | 490 | 1263 | 2314 | |
| DQA1*03 | 3 | 15% | 1739 | 1816 | 364 | 1414 | 2295 | |
| DR7 | 3 | 15% | 825 | 899 | 119 | 805 | 1067 | |
| DPA1*01 | 2 | 10% | 6224 | 6223 | 2882 | 3342 | 9105 | |
| DPA1*03 | 2 | 10% | 5353 | 5353 | 2221 | 3132 | 7574 | |
| DQ2 | 2 | 10% | 808 | 808 | 78 | 730 | 886 | |
| DP26 | 1 | 5% | 1124 | 1124 | - | 1124 | 1124 | |
| DPA1*02 | 1 | 5% | 10288 | 10288 | - | 10288 | 10288 | |

Table 15. Summary of Single Antigen results Serum #066

| Class I *** Serum 66 *** | | | | | | | | |
|-----------------------------|---------|-----------|--------|-------|---------|------|-------|--|
| 19 typing Labs | | | | | | | | |
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| B27 | 19 | 100% | 8642 | 8001 | 2706 | 2104 | 12512 | |
| A3 | 18 | 94% | 4263 | 4134 | 1368 | 1048 | 6880 | |
| B42 | 18 | 94% | 11047 | 9902 | 3529 | 2202 | 16586 | |
| B54 | 18 | 94% | 6476 | 6069 | 2104 | 1495 | 10226 | |
| B55 | 18 | 94% | 8664 | 8174 | 2861 | 1953 | 13287 | |
| B56 | 18 | 94% | 9816 | 8649 | 3198 | 1969 | 14508 | |
| B67 | 18 | 94% | 11074 | 10105 | 3431 | 2298 | 16434 | |
| B7 | 18 | 94% | 12374 | 11494 | 3035 | 3590 | 18112 | |
| B73 | 18 | 94% | 8083 | 7364 | 2799 | 1461 | 12368 | |
| Cw7 | 16 | 84% | 12144 | 11059 | 3972 | 1794 | 17543 | |
| Cw15 | 15 | 78% | 3442 | 3546 | 883 | 2167 | 5648 | |
| B48 | 13 | 68% | 2400 | 2528 | 946 | 1422 | 4323 | |
| B81 | 13 | 68% | 11960 | 10801 | 3750 | 2476 | 17301 | |
| B82 | 13 | 68% | 8557 | 8033 | 2833 | 2184 | 13464 | |
| Cw1 | 13 | 68% | 2897 | 3137 | 929 | 1797 | 4889 | |
| Cw12 | 13 | 68% | 2887 | 3116 | 1036 | 1295 | 4948 | |
| Cw6 | 13 | 68% | 2309 | 2488 | 736 | 1573 | 3869 | |
| Cw16 | 12 | 63% | 3513 | 3665 | 1110 | 1916 | 5755 | |
| Cw14 | 11 | 57% | 2231 | 2404 | 583 | 1658 | 3638 | |
| Cw18 | 11 | 57% | 2002 | 4620 | 7503 | 1320 | 28252 | |
| Cw8 | 11 | 57% | 2244 | 2545 | 708 | 1634 | 3915 | |
| Cw2 | 9 | 47% | 1491 | 1684 | 538 | 1029 | 2598 | |
| B60 | 8 | 42% | 1499 | 1706 | 525 | 1059 | 2540 | |
| B2708 | 6 | 31% | 9416 | 7900 | 4242 | 2121 | 14014 | |
| B8101 | 6 | 31% | 10935 | 8701 | 4520 | 2429 | 13558 | |
| B8201 | 5 | 26% | 8818 | 7941 | 2741 | 2733 | 10842 | |
| Cw5 | 4 | 21% | 1021 | 1128 | 293 | 852 | 1621 | |
| A11 | 2 | 10% | 2143 | 2143 | 1769 | 374 | 3912 | |
| A32 | 2 | 10% | 1024 | 1024 | 296 | 728 | 1320 | |
| A74 | 2 | 10% | 995 | 994 | 264 | 731 | 1258 | |
| B703 | 2 | 10% | 1010 | 1010 | 13 | 997 | 1023 | |
| A210 | 1 | 5% | 1202 | 1202 | - | 1202 | 1202 | |
| A34 | 1 | 5% | 2273 | 2273 | - | 2273 | 2273 | |
| A36 | 1 | 5% | 646 | 646 | - | 646 | 646 | |
| A69 | 1 | 5% | 4437 | 4437 | - | 4437 | 4437 | |
| B41 | 1 | 5% | 1662 | 1662 | - | 1662 | 1662 | |

| Class II *** Serum 66 *** | | | | | | | | |
|------------------------------|---------|-----------|--------|------|---------|------|------|--|
| 8 typing Labs | | | | | | | | |
| Antigen | No.Labs | Consensus | Median | Mean | Std Dev | Min | Max | |
| DPw1 | 5 | 63% | 1229 | 1461 | 540 | 1078 | 2526 | |
| DR18 | 4 | 50% | 1226 | 1071 | 348 | 488 | 1344 | |
| Neg | 3 | 38% | - | - | - | - | - | |
| DP10 | 2 | 25% | 925 | 924 | 561 | 364 | 1485 | |
| DP14 | 2 | 25% | 1021 | 1021 | 536 | 485 | 1557 | |
| DPw5 | 2 | 25% | 1267 | 1266 | 587 | 680 | 1853 | |
| DPw6 | 2 | 25% | 1532 | 1531 | 1046 | 486 | 2577 | |
| DQ4 | 2 | 25% | 1061 | 1060 | 575 | 486 | 1635 | |
| DPA1*01 | 1 | 13% | 1192 | 1192 | - | 1192 | 1192 | |
| DPA1*02 | 1 | 13% | 1229 | 1229 | - | 1229 | 1229 | |

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #56

Table 16. Individual laboratory results for Serum #063 - class I by Luminex

| Center | B44 | B45 | B7 | B18 | B35 | B42 | B55 | B56 | B60 | B62 | B67 | B71 | B72 | B75 | B76 | B8 | B41 | B50 | B54 | B61 | B64 | B48 | B39 | B65 | B82 | B52 |
|--------------|-------|-------|-------|-------|-------|-------|------|-------|------|------|-------|-------|------|-------|-------|-------|-------|-------|------|-------|------|------|-------|------|-------|------|
| 23 | 10819 | 14968 | 9131 | 7924 | 8449 | 10050 | 7323 | 8548 | 7661 | 7597 | 10669 | 7956 | 7633 | 7196 | 14042 | 9023 | 8256 | 8994 | 7920 | 7804 | 7529 | 7007 | 8370 | 4612 | 12034 | 1951 |
| 54 | 16726 | 19967 | 11836 | 10515 | 10449 | 12502 | 9055 | 11168 | 9846 | 9833 | 13406 | 10240 | 9953 | 11352 | 19366 | 11793 | 11105 | 11801 | 9965 | 10415 | 9258 | 9295 | 11490 | 5559 | 17028 | 2081 |
| 206 | 14738 | 18067 | 9303 | 8065 | 8065 | 9749 | 6659 | 8615 | 7604 | 7394 | 10348 | 7918 | 7222 | 7444 | 17935 | 8869 | 8720 | 9232 | 7796 | 8189 | 6707 | 7224 | 8345 | 3853 | 14992 | |
| 230 | 18337 | 20738 | | | | | | | | | | | | | | | | | | | | | | | | |
| 615 | | | 9998 | 9383 | | | | | | | | | | | | | | | | | | | | | | |
| 774 | 15282 | 18074 | 8788 | 8064 | 7992 | 9373 | 7255 | 8676 | 6775 | 7607 | 10036 | 8005 | 7693 | 8887 | 17578 | 8526 | 8120 | 8969 | 7364 | 7806 | 6890 | 6719 | 8796 | | 14173 | |
| 792 | 12462 | 15332 | 8224 | 7168 | 7739 | 8544 | 6565 | 7571 | 6820 | 6991 | 9132 | 6959 | 7110 | 7878 | 14076 | 7713 | 7562 | 8388 | 7022 | 7262 | 6307 | 6206 | 8110 | 3932 | 12569 | 1996 |
| 836 | 16925 | 19557 | 10047 | 8427 | 8970 | 9989 | 9499 | 9047 | 8112 | 8405 | 11007 | 8802 | 8449 | 9345 | 18266 | 9515 | 9490 | 9829 | 8425 | 8899 | 7542 | 8990 | 8233 | 4551 | | 2168 |
| 1160 | 16058 | 19173 | 10669 | 9298 | 9687 | 11268 | 8528 | 9781 | 9032 | 9002 | 11968 | 9806 | 8625 | 9903 | 17867 | 10085 | 10071 | 10405 | 8736 | 9592 | 8141 | 8750 | 10602 | 4980 | 14318 | 1399 |
| 2400 | 14203 | 18532 | 8313 | 7040 | 7562 | 9112 | 5747 | 7356 | 6603 | 6414 | 8164 | 7192 | 6619 | 7519 | 17031 | 8815 | 8129 | 8125 | 8182 | 7203 | 6542 | 5906 | 8104 | 3884 | 13669 | |
| 3224 | 15515 | 18453 | 10846 | 9351 | 9919 | 11483 | 8485 | 10482 | 8712 | 9013 | 11872 | 9483 | 8885 | 9895 | 16579 | 10308 | 9851 | 10734 | 9368 | 9717 | 8397 | 7920 | | 5247 | | 1890 |
| 3625 | 11438 | 13484 | 5661 | 4718 | 5238 | 5786 | 4441 | 5586 | 4566 | 4718 | 6337 | 4654 | 5269 | 6776 | 12135 | 5837 | 4896 | 6276 | 5126 | 5261 | 3846 | 4136 | | 2569 | | 2003 |
| 3753 | 14245 | 17686 | 5497 | 4637 | 5045 | 5224 | 4198 | 4814 | 4761 | 4757 | 5519 | 5003 | 4557 | 4126 | 15185 | 4861 | 5689 | 6177 | 4488 | 5063 | 3610 | 3940 | 5752 | 2182 | 12410 | 1413 |
| 4661 | 4573 | 6285 | 2458 | 1567 | 2008 | 2318 | 2044 | 2085 | 1505 | 2129 | 2544 | 2156 | 2009 | 1782 | 5292 | 2002 | 1766 | 2366 | 2132 | 1460 | 1612 | | | | | |
| 8001 | 17008 | 19543 | 10298 | 9408 | 9564 | 10864 | 8619 | 10146 | 8700 | 9246 | 11190 | 9632 | 9063 | 10087 | 17867 | 10335 | 9939 | 10494 | 9274 | 9617 | 8427 | 8386 | 10057 | 4975 | 15626 | 1814 |
| 8050 | 14630 | 19229 | 9001 | 7905 | 8193 | 9297 | 6721 | 8229 | 7286 | 7476 | 10801 | 8131 | 7306 | 7334 | 17420 | 8941 | 8145 | 9124 | 7604 | 7815 | 6791 | 6911 | 9123 | 3664 | 14287 | |
| 8083 | 13664 | 16434 | 7588 | 6423 | 7058 | 7759 | 5560 | 6903 | 6215 | 5914 | 8180 | 6557 | 6010 | 6991 | 14076 | 6954 | | 7656 | 6221 | 6819 | 5401 | 5781 | 7056 | 3355 | | 1888 |
| 8096 | 6738 | 9615 | 4358 | | 4442 | 5842 | 3830 | 3666 | 3501 | 4013 | 5076 | 5019 | 5015 | 2735 | 6521 | 6036 | 5386 | | | | | | 4302 | | 3808 | |
| 8103 | 4323 | 5227 | 1877 | 1386 | 1571 | 1821 | 1557 | 1552 | 1451 | 1615 | 2116 | 1625 | 1539 | 1569 | 4590 | 1758 | 1406 | 1901 | 1667 | 1431 | 1481 | 797 | 1563 | 869 | 5507 | 716 |
| Avg | 13205 | 16131 | 7994 | 7134 | 7174 | 8293 | 6240 | 7307 | 6421 | 6596 | 8727 | 7008 | 6645 | 7107 | 14460 | 7728 | 7408 | 8154 | 6956 | 7147 | 6155 | 6531 | 7850 | 3874 | 12535 | 1756 |
| Std | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dev.S | 4173 | 4644 | 2885 | 2652 | 2645 | 3102 | 2380 | 2864 | 2494 | 2435 | 3336 | 2559 | 2357 | 2945 | 4706 | 2836 | 2860 | 2794 | 2457 | 2682 | 2364 | 2256 | 2574 | 1303 | 3952 | 424 |
| %CV | 32% | 29% | 36% | 37% | 37% | 37% | 38% | 39% | 39% | 37% | 38% | 37% | 35% | 41% | 33% | 37% | 39% | 34% | 35% | 38% | 35% | 33% | 34% | 32% | 24% | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 16. Individual laboratory results for Serum #063 - class I by Luminex - cont.

| Center | B78 | B81 | B27 | B2708 | B49 | Bw6 | B7801 | B8101 | B3901 | B8201 | Other | Manufacturer |
|--------------|------|-------|-------|-------|------|------------|-------|-------|-------|-------|------------------|--------------|
| 23 | 6734 | 8732 | | 9900 | 2361 | 8122 | | | | | B73,Cw1,Cw9,Cw8 | One Lambda |
| 54 | 8694 | 11484 | 12770 | | | 1498 | | | | | | One Lambda |
| 206 | 6437 | 8553 | | | | | | | | | | One Lambda |
| 230 | | | | | | 10182 | | | | | | One Lambda |
| 615 | | | | | | | | | | | | |
| 774 | 6509 | 8242 | 9662 | | | | | | | | | One Lambda |
| 792 | 6024 | 7980 | 8512 | | | 1868 | | | | | B13,B47,B73,Cw1> | One Lambda |
| 836 | | | | 10451 | 1686 | 19557 | 7327 | 9198 | 9547 | 15616 | B4005,B3902 | One Lambda |
| 1160 | 8007 | 10176 | | 11032 | | 19173 | | | | | | One Lambda |
| 2400 | 5730 | 8950 | 8571 | | | | | | | | | One Lambda |
| 3224 | | | | 11357 | 1619 | | 8113 | 10356 | 10515 | 15471 | | One Lambda |
| 3625 | | | | 6089 | 1660 | | 4050 | 5250 | 5287 | 9907 | | One Lambda |
| 3753 | 3862 | 5056 | | 5964 | | 6819 | | | | | | One Lambda |
| 4661 | | | 3198 | | | | 1577 | 1524 | 2119 | 6730 | | Lifecodes |
| 8001 | 8036 | 10060 | | 10976 | 1214 | 19543 | | | | | | One Lambda |
| 8050 | 6494 | 8335 | | 9818 | | 8940 | | | | | | One Lambda |
| 8083 | | | 7745 | | 1625 | | 5598 | 6699 | | 13080 | | One Lambda |
| 8096 | | | 2812 | | 2436 | | | | | | A66,A34,A30,A31> | One Lambda |
| 8103 | 1322 | 1810 | 2239 | 2239 | | 5507 | 1322 | 1810 | 1563 | | A24,B40,B15,B51> | Immucor |
| Avg | 6168 | 8125 | 6939 | 8647 | 1774 | 12230 | 4665 | 5806 | 5806 | 12161 | | |
| Std | | | | | | | | | | | | |
| Dev.S | 2071 | 2643 | 3786 | 3152 | 395 | 6115 | 2861 | 3677 | 4124 | 3818 | | |
| %CV | 34% | 33% | 55% | 36% | 22% | 50% | 61% | 63% | 71% | 31% | | |

DSA present**Blue** = DSA against cell #061 only**Gold** = DSA against cell #062 only**Green** = DSA against cell #061 and #62

Table 17. Individual laboratory results for Serum #064 - class I by Luminex

| Center | B8 | A32 | B42 | B54 | B7 | Cw1 | Other | Manufacturer |
|--------------|------|------|------|------|-----------|------|------------|--------------|
| 23 | 4687 | 1530 | | | | | | One Lambda |
| 54 | 7870 | 2157 | 1648 | | | 2246 | Cw12 | One Lambda |
| 206 | 7286 | | | | | | | One Lambda |
| 230 | 7783 | 2286 | | | | | | One Lambda |
| 615 | | | | | | | | |
| 774 | 6033 | | | | | | | One Lambda |
| 792 | 6183 | 1795 | 1025 | 982 | 986 | 1679 | B60,B48> | One Lambda |
| 836 | 6489 | 2072 | 1599 | 1084 | 1085 | 1218 | | One Lambda |
| 1160 | 5939 | 1327 | | | | | | One Lambda |
| 2400 | 5785 | | | | | | | One Lambda |
| 3224 | 5997 | 1631 | 1112 | | | | | One Lambda |
| 3625 | 4352 | | | | | | | One Lambda |
| 3753 | 5447 | 1351 | | | | | | One Lambda |
| 4661 | 802 | | | | | | | Lifecodes |
| 8001 | 6487 | 1701 | 1229 | 1090 | 1143 | | B81 | One Lambda |
| 8050 | 5947 | | | | | | | One Lambda |
| 8083 | 8838 | 3390 | 1156 | 1504 | 1164 | | A1,B76,B59 | One Lambda |
| 8096 | 1232 | | | | | | A80 | One Lambda |
| 8103 | 1054 | | | | | | | Immucor |
| Avg | 5456 | 1924 | 1295 | 1165 | 1095 | 1714 | | |
| Std | | | | | | | | |
| Dev.S | 2308 | 610 | 263 | 231 | 80 | 515 | | |
| %CV | 42% | 32% | 20% | 20% | 7% | 30% | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 18. Individual laboratory results for Serum #065 - class I by Luminex

| Center | A23 | A24 | A25 | A32 | B57 | B27 | B49 | B58 | B59 | B38 | B44 | B53 | B63 | B77 | B51 | B52 | B37 | B13 | A80 | B47 | Bw4 | A2 | A2403 | B76 | Other | Manufacturer |
|--------------|-------|-------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-------|------------------|------------|--------------|
| 23 | 8690 | 7976 | 6766 | 7381 | 6352 | 3791 | 5893 | 6499 | 4540 | 5831 | 3392 | 5552 | 5586 | 4684 | 5565 | 4512 | 3697 | 3168 | 1340 | 2291 | 4434 | | | | One Lambda | |
| 54 | 10941 | 10913 | 8306 | 9099 | 8435 | 4251 | 7054 | 7952 | 4982 | 7098 | 4581 | 6174 | 7261 | 5642 | 6746 | 5342 | 3947 | 3925 | 2789 | 2577 | | 1451 | | 1798 | | |
| 206 | 8472 | 7592 | 5788 | 7238 | 6368 | 3146 | 5372 | 5969 | 4010 | 5214 | | 4937 | 5347 | 4252 | 5151 | 4030 | 3299 | | | | | | | | One Lambda | |
| 230 | 10408 | 10443 | 7328 | 8432 | 7524 | | | | | | | | | | | | | | | 2155 | | 5740 | | | One Lambda | |
| 615 | | | | | | | 5809 | 3095 | | | | | | | | | | | | | | | | | | |
| 774 | 5920 | 5117 | 4212 | 4816 | 5346 | 2123 | 3803 | 4771 | 3182 | 4175 | 2235 | 3907 | 4575 | 3262 | 4174 | 3144 | 2378 | | | | | | | | One Lambda | |
| 792 | 7842 | 7961 | 5510 | 6242 | 5497 | 3097 | 4853 | 5308 | 3763 | 4908 | 3117 | 4598 | 4493 | 3949 | 4971 | 3858 | 3062 | 2600 | 1780 | 1745 | | 885 | | 1159 A1,A68,A69> | One Lambda | |
| 836 | 8001 | 8273 | 5439 | 6072 | 5452 | 6016 | 4785 | 5257 | 3738 | 6171 | 3016 | 4716 | 8880 | 3934 | 4845 | 3702 | 2794 | 2432 | 1681 | 1598 | | 1383 | 6729 | | B62,A210 | One Lambda |
| 1160 | 9672 | 8775 | 6490 | 7820 | 6944 | 3559 | 5960 | 6540 | 4234 | 6045 | 3558 | 5523 | 5731 | 4476 | 5987 | 4574 | 3463 | 3048 | 1785 | 2040 | 6944 | 1014 | | 1069 A68,A69 | One Lambda | |
| 2400 | 6981 | 6691 | 4367 | 5138 | 5481 | 2293 | 3969 | 4809 | 2891 | 4112 | 2480 | 3603 | 5342 | 4448 | 4471 | 3263 | | | | | | | | | One Lambda | |
| 3224 | 10217 | 10318 | 7660 | 8066 | 7424 | 3851 | 6320 | 7210 | 5124 | 6573 | 4091 | 6075 | 6372 | 5084 | 6461 | 4988 | 3481 | 3484 | 2249 | 2272 | 7424 | 1335 | 8769 | | One Lambda | |
| 3625 | 4621 | 4390 | 3434 | 3983 | 3469 | 1593 | 2952 | 3060 | 2652 | 2670 | 2062 | 2810 | 2630 | 2481 | 3153 | 2404 | 1678 | 1370 | | | | | 3605 | | One Lambda | |
| 3753 | 7108 | 6075 | 5090 | 6261 | 5651 | 2900 | 5038 | 5881 | 4092 | 5160 | 2556 | 4933 | 4819 | 3663 | 4916 | 3858 | 2954 | 2332 | 1709 | 1731 | | | | | One Lambda | |
| 4661 | 1892 | 2128 | 1499 | 1807 | 1554 | 826 | 1225 | 1200 | 910 | 1176 | 859 | 1230 | 1490 | 1012 | 599 | 670 | 598 | 318 | | 490 | | | 1771 | | Lifecodes | |
| 8001 | 9352 | 9758 | 6827 | 7049 | 6855 | 3602 | 5873 | 6589 | 4763 | 5969 | 3672 | 5580 | 5771 | 4924 | 6155 | 4563 | 3407 | 3112 | 1860 | 2202 | 6855 | 1123 | | 1111 | One Lambda | |
| 8050 | 5658 | 4103 | 4180 | 5550 | 4892 | 2323 | 4196 | 4963 | 3149 | 4485 | 1923 | 3823 | 4150 | 3302 | 4120 | 3165 | 2299 | 1677 | 1547 | 1204 | 3311 | | | | One Lambda | |
| 8083 | 4341 | 4331 | 2764 | 2961 | 2733 | 1364 | 2330 | 2751 | 1849 | 2435 | 1449 | 2483 | 2081 | 1872 | 2444 | 1899 | 1424 | 1122 | | | | | | | One Lambda | |
| 8096 | 551 | 494 | 353 | 654 | | 503 | 544 | | 501 | | 531 | | | | | | | | | 406 | | | | B54,B41,Cw7 | One Lambda | |
| 8103 | 1708 | 1827 | 1106 | 1282 | 1134 | | 983 | 969 | 913 | 1027 | 773 | 1022 | 1166 | 870 | | | | | | | 1827 | | 1545 | | B15 | Immucor |
| Avg | 6799 | 6509 | 4840 | 5547 | 5384 | 2843 | 4185 | 5104 | 3253 | 4566 | 2518 | 4185 | 4731 | 3616 | 4651 | 3598 | 2749 | 2382 | 1755 | 1815 | 5219 | 1199 | 4484 | 1284 | | |
| Std | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dev.S | 3140 | 3144 | 2312 | 2522 | 2007 | 1362 | 1970 | 2034 | 1462 | 1865 | 1212 | 1608 | 2081 | 1415 | 1628 | 1237 | 966 | 1071 | 594 | 615 | 2103 | 226 | 3169 | 344 | | |
| %CV | 46% | 48% | 48% | 45% | 37% | 48% | 47% | 40% | 45% | 41% | 48% | 38% | 44% | 39% | 35% | 34% | 35% | 45% | 34% | 34% | 40% | 19% | 71% | 27% | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 19. Individual laboratory results for Serum #066 - class I by Luminex

| Center | B27 | A3 | B42 | B54 | B55 | B56 | B67 | B7 | B73 | Cw7 | Cw15 | B48 | B81 | B8101 | B82 | B8201 | Cw1 | Cw12 | Cw6 | Cw16 | Cw14 | Cw18 | Cw8 | Other | Manufacturer | |
|------------------|-------|------|-------|-------|-------|-------|-------|-------|-------|-------|------|------|-------|-------|-------|-------|------|------|------|------|------|-------|------|--------------|--------------|------------|
| 23 | 7057 | 3604 | 9176 | 5800 | 7087 | 7679 | 9399 | 9505 | 7019 | 9035 | 2518 | 1422 | 9359 | | 7441 | 2438 | 1988 | 1650 | 2250 | 1658 | 1320 | 1698 | | One Lambda | | |
| 54 | 5705 | 3045 | 8618 | 4502 | 5775 | 5989 | 8504 | 9774 | 5672 | 9815 | 3462 | | 7459 | | 6016 | | 2004 | 2199 | 1573 | 1916 | | | 1634 | | | |
| 206 | 9613 | 4983 | 12244 | 6772 | 9037 | 10479 | 12393 | 12738 | 8472 | | | | 12739 | | 9532 | | | | | | | | | | One Lambda | |
| 230 | 12512 | 6880 | 16586 | 10226 | 13287 | 14508 | 16434 | 18112 | 12368 | 17543 | 5648 | 3972 | 17301 | | 13464 | | 4839 | 4727 | 3869 | 5755 | 3638 | 3077 | 3915 | B2708,B60> | One Lambda | |
| 615 | 7688 | | | | | | | 11086 | | 9472 | 2660 | | | | | | | | 1829 | | | | | | | |
| 774 | 10157 | 4788 | 11146 | 7387 | 9291 | 10123 | 11127 | 12344 | 9327 | 12785 | | 2052 | 11960 | | 9184 | | | | | | | | | | One Lambda | |
| 792 | 8234 | 4000 | 9490 | 6158 | 7929 | 8585 | 9683 | 10338 | 7628 | 9672 | 3051 | 2188 | 10367 | | 7940 | | 2609 | 2556 | 2078 | 2948 | 1966 | 1718 | 2168 | B60,A11,A25> | One Lambda | |
| 836 | 8642 | 4215 | 11102 | 6618 | 12078 | 9834 | 11294 | 12617 | 8364 | 11797 | 3620 | 2454 | | 11876 | | 8999 | 2980 | 3003 | 2324 | 3676 | 2177 | 1875 | 2362 | B60,B2708> | One Lambda | |
| 1160 | 9103 | 4155 | 10992 | 5868 | 8452 | 9030 | 11021 | 11972 | 7802 | | 2167 | 1434 | 11431 | | 8488 | | 1797 | | | | | | | | One Lambda | |
| 2400 | 9053 | 4365 | 11991 | 7202 | 9457 | 10709 | 12507 | 12824 | 8818 | 13236 | 3337 | 2509 | 13792 | | 9513 | | 2793 | 2887 | 2309 | 3243 | 2244 | | | | One Lambda | |
| 3224 | 8836 | 4310 | 11488 | 7006 | 8781 | 10015 | 11641 | 12404 | 8511 | 9617 | 3078 | 2039 | | 11589 | | 8818 | 2753 | 2798 | 1986 | 2893 | 2110 | 1732 | 2164 | B60,B2708> | One Lambda | |
| 3625 | 8164 | 3950 | 10544 | 6333 | 8547 | 9797 | 9966 | 11264 | 7700 | 13257 | 3186 | 2448 | | 10281 | | 8314 | 2897 | 2800 | 2278 | 3444 | 1993 | 2198 | 2244 | B60,B2708> | One Lambda | |
| 3753 | 7876 | 5457 | 9741 | 5880 | 8365 | 9054 | 10224 | 12745 | 7234 | 14299 | 4647 | 4069 | 12755 | | 8557 | | 4099 | 4382 | 3506 | 4999 | 2800 | 28252 | 3019 | B60,Cw2 | One Lambda | |
| 4661 | 2104 | 1310 | 2712 | 1722 | 2768 | 2467 | 2842 | 3590 | 1730 | 1794 | | | | 2429 | | 2733 | | | | | | | | | B2708,B703 | Lifecodes |
| 8001 | 10383 | 4349 | 12282 | 6969 | 9886 | 10682 | 12197 | 12981 | 8649 | 12491 | 3669 | 2400 | 12986 | | 10003 | | 3193 | 3199 | 2549 | 3582 | 2271 | 1889 | 2238 | B60,Cw2 | One Lambda | |
| 8050 | 9006 | 4386 | 11465 | 6799 | 9625 | 10528 | 12109 | 12703 | 8503 | 14288 | 3442 | 1562 | 12605 | | 9076 | | 3491 | 3731 | 2665 | 4225 | 2231 | 2002 | 2910 | Cw2 | One Lambda | |
| 8083 | 11475 | 6051 | 12446 | 8877 | 10624 | 11114 | 12861 | 14120 | 10683 | 14719 | 4767 | 4323 | | 13558 | | 10842 | 4889 | 4948 | 3739 | 5054 | 3366 | 3332 | 3651 | B60,A32,A74> | One Lambda | |
| 8096 | 4301 | 3523 | 4019 | 3628 | 4207 | 3127 | 5398 | 5790 | 2620 | | 3945 | | 5188 | | 3033 | | 1295 | | | | | | | 3435 | A11,B49,A34, | One Lambda |
| 8103 | 2121 | 1048 | 2202 | 1495 | 1953 | 1969 | 2298 | | 1461 | 3129 | | | 2476 | 2476 | 2184 | | | | | | | | | | B2708,B703> | Immucor |
| Avg | 8002 | 4134 | 9902 | 6069 | 8175 | 8649 | 10105 | 11495 | 7365 | 11059 | 3546 | 2529 | 10801 | 8702 | 8033 | 7941 | 3137 | 3116 | 2489 | 3665 | 2405 | 4621 | 2546 | | | |
| Std Dev.S | 2781 | 1408 | 3631 | 2165 | 2944 | 3291 | 3530 | 3123 | 2880 | 4102 | 914 | 985 | 3903 | 4952 | 2949 | 3065 | 967 | 1078 | 766 | 1160 | 611 | 7869 | 742 | | | |
| %CV | 35% | 34% | 37% | 36% | 36% | 38% | 35% | 27% | 39% | 37% | 26% | 39% | 36% | 57% | 37% | 39% | 31% | 35% | 31% | 32% | 25% | 170% | 29% | | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 20. Individual laboratory results for Serum #063 - class II by Luminex

| Center | Class II NEG | Manufacturer |
|--------|--------------|--------------|
| 23 | | One Lambda |
| 54 | | One Lambda |
| 206 | | One Lambda |
| 230 | | One Lambda |
| 615 | | |
| 774 | | One Lambda |
| 792 | | One Lambda |
| 836 | | One Lambda |
| 1160 | | One Lambda |
| 2400 | | One Lambda |
| 3224 | | One Lambda |
| 3625 | | One Lambda |
| 3753 | | One Lambda |
| 4661 | | Lifecodes |
| 8001 | | One Lambda |
| 8050 | | One Lambda |
| 8083 | | One Lambda |
| 8096 | | One Lambda |
| 8103 | | Immucor |
| | | |
| | | |
| | | |
| | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 21. Individual laboratory results for Serum #064 - class II by Luminex

| Center | DR53 | DR7 | DR1 | DR10 | DR103 | DR4 | DR51 | DR9 | DR14 | DR15 | DQ2 | DP14 | DP17 | Other | Manufacturer |
|--------------|------|------|-------|------|-------|-------|------|------|-------|------|------|------|------|-------------------------------|--------------|
| 23 | 2107 | 3909 | 8958 | 2065 | 3432 | 3256 | 3443 | 2521 | | | | | | | One Lambda |
| 54 | 4845 | 6637 | 16539 | 3935 | 7176 | 12174 | 6719 | 5626 | 10047 | 4379 | | | | | One Lambda |
| 206 | 4380 | 6213 | 14701 | 4174 | 6939 | 10051 | 6242 | 4949 | 9867 | | | | | | One Lambda |
| 230 | 5180 | 6616 | 17606 | 4164 | 7175 | 8309 | 7178 | 5899 | | | | | | | One Lambda |
| 615 | 4294 | 6188 | | | | | | | | | | | | | |
| 774 | 4327 | 5765 | 15017 | 3398 | 5972 | 11704 | 6170 | 5003 | 9515 | 4200 | | | | | One Lambda |
| 792 | 4106 | 5292 | 12808 | 3353 | 5824 | 9610 | 5843 | 4594 | 8297 | 3736 | 1559 | 707 | 799 | DQ4,DQ5,DQ7,DQ8 > | One Lambda |
| 836 | 4437 | 6069 | 15176 | 3775 | 6354 | 10962 | 6428 | 5246 | 9479 | 4152 | 1358 | | | DP26,DPA1*02,DPA1*03,DQA1*02> | One Lambda |
| 1160 | 4022 | 5490 | 15127 | 3596 | 5447 | 9837 | 6772 | 4081 | 7335 | 3515 | 1399 | 730 | 668 | DPw1,DPw3,DPw5,DPw6 > | One Lambda |
| 2400 | 3276 | 4978 | 12129 | 3101 | 5251 | 8203 | 4888 | 3859 | 7918 | 3455 | | | | | One Lambda |
| 3224 | 3801 | 5772 | 14164 | 3367 | 5497 | 8716 | 6438 | 4307 | 7173 | 3752 | | | | | One Lambda |
| 3625 | 1851 | 2462 | 7418 | 1320 | 2575 | 5617 | 2878 | 1669 | 4648 | 1695 | | | | | One Lambda |
| 3753 | 4081 | 6883 | 13099 | 3585 | 6301 | | 5614 | 4205 | | | | | | | One Lambda |
| 4661 | 1080 | 1794 | 4529 | 1086 | 1711 | 3826 | 1979 | 1482 | | 651 | | | | | Lifecodes |
| 8001 | 4822 | 5937 | 15679 | 3902 | 6819 | 11483 | 7024 | 5377 | 10033 | 4377 | 1321 | | | DQA1*05 | One Lambda |
| 8050 | 4416 | 6691 | 16021 | 3851 | 6498 | 10301 | 6647 | 4628 | 8829 | 2851 | | | | | One Lambda |
| 8083 | 2693 | 3108 | 8743 | 1780 | 4212 | 6486 | 3645 | 3017 | 4451 | 2745 | | | | | One Lambda |
| 8096 | 4685 | 4872 | 11768 | 2705 | 2463 | 9634 | | | 9607 | | 4495 | 4752 | 2001 | DR13,DR16 | One Lambda |
| 8103 | 840 | 1285 | 2491 | 662 | 980 | 2513 | 1275 | 1016 | | 562 | | | | | Immucor |
| Avg | 3644 | 5051 | 12332 | 2990 | 5035 | 8393 | 5246 | 3969 | 8246 | 3082 | 2026 | 2063 | 1156 | | |
| Std | | | | | | | | | | | | | | | |
| Dev.S | 1303 | 1722 | 4268 | 1119 | 1982 | 3023 | 1879 | 1507 | 1911 | 1333 | 1383 | 2329 | 735 | | |
| MFI | | | | | | | | | | | | | | | |
| %CV | 36% | 34% | 35% | 37% | 39% | 36% | 36% | 38% | 23% | 43% | 68% | 113% | 64% | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 22. Individual laboratory results for Serum #065 - class II by Luminex

| Center | DR53 | DR11 | DR4 | DPw3 | DP14 | DP17 | DP18 | DP28 | DP9 | DPw2 | DPw6 | DR10 | DR14 | DP10 | DP20 | DR1 | DR9 | DP402 | DQ8 | DPw4 | DQ7 | DQ9 | DP11 | DQ4 | DPw1 | Other | Manufacturer | |
|--------|-------|------|-------|------|------|------|------|------|------|-------|------|------|------|------|------|------|------|-------|------|-------|------|------|------|------|------|------------|--------------|------------|
| 23 | 5950 | 4242 | 11580 | 5674 | 5691 | 4971 | 5792 | 5482 | 5542 | 6278 | 4871 | 2275 | 992 | 4776 | 6204 | | 1729 | 6837 | | | 1085 | | | | | DP401 | One Lambda | |
| 54 | 15781 | 5973 | 19425 | 9617 | 7983 | 7788 | 9686 | 9061 | 7885 | 10723 | 7620 | 4402 | 3497 | 7413 | 9166 | 3129 | 2874 | | 2287 | 10912 | 1914 | 2117 | | | | | DP19 | One Lambda |
| 206 | 14179 | 5447 | 17411 | | | | | | | | | 4165 | 3330 | | | | | | | | | | | | | | | One Lambda |
| 230 | 15668 | 5511 | 19246 | 9130 | 7380 | 6859 | 8545 | 8684 | 7513 | 9825 | 7123 | 3770 | 3293 | 6951 | 8415 | 2520 | 2717 | 10097 | 2311 | | | | | | | | One Lambda | |
| 615 | 11802 | | | 7252 | | | | | | | | 2792 | | | | | | | | | | 1706 | | | 1746 | | | |
| 774 | 13875 | 5032 | 17824 | 7778 | 6458 | 6381 | 7760 | 7792 | 6522 | 9368 | 6400 | 3571 | 2688 | 6493 | 7977 | 2452 | 2172 | | | 8458 | | | | | | | One Lambda | |
| 792 | 12004 | 5218 | 14641 | 7410 | 6019 | 6073 | 7608 | 7272 | 6210 | 8286 | 6224 | 3477 | 2794 | 5693 | 7045 | 2495 | 2362 | | 1955 | 8215 | 1630 | 1857 | 1659 | 1513 | 1256 | DP19,DP23> | One Lambda | |
| 836 | 14326 | 5120 | 19771 | 8128 | 6276 | 6006 | 7545 | 7857 | 6379 | 8882 | 6589 | 3694 | 3239 | 6108 | 7574 | 2589 | 2424 | 9105 | 2295 | | 1641 | 1988 | 2119 | 1733 | 1706 | DP19,DP23> | One Lambda | |
| 1160 | 13027 | 4371 | 19380 | 8839 | 6794 | 6142 | 8964 | 8845 | 7396 | 8563 | 6752 | 2632 | 2272 | 6887 | 8103 | 1300 | 2475 | | 2653 | 9472 | 2079 | 2248 | | 1554 | | DR7,DQ2,DF | One Lambda | |
| 2400 | 11465 | 3877 | 17831 | 6164 | 5007 | 4850 | 5857 | 5551 | 5537 | 7810 | 4955 | 2452 | 2285 | 4911 | 6734 | | | | 7397 | | | | | | | | One Lambda | |
| 3224 | 13139 | 5301 | 17734 | 9233 | 6839 | 6584 | 8912 | 9321 | 7725 | 8834 | 6997 | 3372 | 3438 | 7094 | 8423 | 1917 | 3235 | 9805 | 2554 | | 1886 | 2150 | 1799 | | | | DP19,DP23> | One Lambda |
| 3625 | 7295 | 3505 | 13086 | 4662 | 3722 | 4005 | 4793 | 4590 | 4357 | 5349 | 3848 | 1935 | 1310 | 3659 | 4196 | 1261 | | 5164 | | | | | | | | | One Lambda | |
| 3753 | 10896 | 2297 | 17975 | 4312 | 3464 | 3367 | 4127 | 3930 | 3794 | 5432 | 3506 | 2159 | | 3526 | 4687 | 1392 | | 5648 | | | | | | | | DQA1*03 | One Lambda | |
| 4661 | 862 | 457 | 3464 | 656 | 450 | 454 | 669 | 545 | 496 | 799 | 628 | | | | | | | 880 | | | | | | | | | Lifecodes | |
| 8001 | 14406 | 4936 | 20032 | 8607 | 6916 | 6663 | 8107 | 8471 | 7009 | 9766 | 6725 | 3365 | 3057 | 6620 | 8063 | 2540 | 2455 | | 2367 | 9755 | 1754 | 2003 | 2138 | 1689 | 1758 | DP19,DP23> | One Lambda | |
| 8050 | 12760 | 3850 | 17157 | 7002 | 5803 | 5900 | 6875 | 6701 | 6761 | 7764 | 6027 | 2690 | | 6196 | 6830 | | 1743 | 9142 | | | | | | | | | One Lambda | |
| 8083 | 12509 | 4656 | 17644 | 7211 | 5591 | 5375 | 6942 | 6935 | 5790 | 8088 | 5958 | 3031 | 2715 | 5382 | 6833 | 2360 | 2324 | | 2170 | 8046 | 1534 | 1827 | 1889 | 1614 | 1616 | DP19,DP23> | One Lambda | |
| 8096 | 9269 | 7965 | 12917 | | | | | | | | | 2323 | | | 4592 | 3657 | 7236 | 12980 | | | | 1931 | | | | DR8,DR12> | One Lambda | |
| 8103 | 3339 | 1987 | 8575 | 2894 | 1886 | 1665 | 2836 | 2136 | 1869 | 3342 | 2784 | | | | | | | 3306 | | 3306 | | | | | | DPA1*01> | Immucor | |
| Avg | 11187 | 4430 | 15872 | 6739 | 5392 | 5193 | 6564 | 6448 | 5674 | 7444 | 5438 | 3133 | 2668 | 5836 | 7161 | 2379 | 2514 | 6722 | 3508 | 8195 | 1690 | 1987 | 1923 | 1621 | | | | |
| Std | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dev.S | 4114 | 1671 | 4440 | 2444 | 2050 | 1961 | 2448 | 2578 | 2106 | 2619 | 1896 | 749 | 741 | 1239 | 1413 | 913 | 556 | 3020 | 3558 | 2270 | 302 | 183 | 185 | 91 | | | | |
| MFI | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| %CV | 37% | 38% | 28% | 36% | 38% | 38% | 37% | 40% | 37% | 35% | 35% | 24% | 28% | 21% | 20% | 38% | 22% | 45% | 101% | 28% | 18% | 9% | 10% | 6% | | | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Table 23. Individual laboratory results for Serum #066 - class II by Luminex

| Center | NEG | DPw1 | DR18 | DP10 | DP14 | DPw5 | DPw6 | DQ4 | Other | Manufacturer |
|------------------|------|------|------|------|------|------|------|------|-----------------|--------------|
| 23 | | | 1118 | | | | | | | One Lambda |
| 54 | | | | | | | | | | One Lambda |
| 206 | | | | | | | | | | One Lambda |
| 230 | | | | | | | | | | One Lambda |
| 615 | 1350 | 1334 | | | | | | | | |
| 774 | | | | | | | | | | One Lambda |
| 792 | 1078 | 488 | 364 | 485 | 680 | 486 | 486 | DR53 | | One Lambda |
| 836 | 1229 | | | | | | | | DPA1*01,DPA1*02 | One Lambda |
| 1160 | | | | | | | | | | One Lambda |
| 2400 | | | | | | | | | | One Lambda |
| 3224 | | | | | | | | | | One Lambda |
| 3625 | | | | | | | | | | One Lambda |
| 3753 | 0 | | | | | | | | | One Lambda |
| 4661 | | | | | | | | | | Lifecodes |
| 8001 | 1125 | | | | | | | | | One Lambda |
| 8050 | | | | | | | | | | One Lambda |
| 8083 | 2526 | 1344 | 1485 | 1557 | 1853 | 2577 | 1635 | | | One Lambda |
| 8096 | 0 | | | | | | | | | One Lambda |
| 8103 | 0 | | | | | | | | | Immucor |
| Avg | 1462 | 1071 | 925 | 1021 | 1267 | 1532 | 1061 | | | |
| Std Dev.S | 604 | 402 | 793 | 758 | 829 | 1479 | 812 | | | |
| MFI %CV | 41% | 38% | 86% | 74% | 65% | 97% | 77% | | | |

DSA present

Blue = DSA against cell #061 only

Gold = DSA against cell #062 only

Green = DSA against cell #061 and #62

Virtual Crossmatch Results

Table 24. Individual Virtual crossmatch results for Serum #65 vs Donor #V1

Donor #V1 - HLA genotype: A*24:10-A*33:03-B*18:02-B*56:04-C*01:02:01G-C*07:04:01G/DRB1*09:01:02G-DRB1*12:02-DRB3*03:01-DRB4*01:01:01G-DQB1*03:01-DQB1*03:03-DPB1*04:01:01G-DPB1*05:01:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|---|---------------------------|--|-----------------|--|
| 23 | 65 | | Positive | A24 (7976) | Positive | DR9 (1729) DR53 (5951) DQ7 (1084) DP401 (1263) | Unacceptable | |
| 54 | 65 | 98 | Positive | A24 (10913) | Positive | DR53 (15781) DQ7 (1914) DQ9 (2117) DPw4 (2210) | Unacceptable | |
| 206 | 65 | 86% | Positive | A24 (7592) | Positive | DR53 (14179) | Unacceptable | |
| 230 | 65 | 94 | Positive | A24 (10443) | Positive | DR9 (2717) DR53 (15668) DP401 (2238) | Unacceptable | |
| 774 | 65 | 93 | Positive | A24 (5117) | Positive | DR9 (2172) DR53 (13875) DPw4 (8458) | Unacceptable | |
| 792 | 65 | 100 | Likely positive | A24 (7961) | Positive | DR9 (1249) DR53 (9344) DQ7 (1630) DQ9 (1857) DP401 (1792) | Unacceptable | No A*24:10 bead on SAB panel but other A*24 beads are positive |
| 836 | 65 | 99 | Positive | A24 (8273) A2403 (6729) | Positive | DR53 (11970) DQ7 (1625) DQ9 (1988) DPw4 (2291) | Unacceptable | |
| 1160 | 65 | 93 | Positive | A24 (8775) | Positive | DR9 (1216) DR53 (12128) DQ7 (2079) DQ9 (2248) DP401 (1906) | Unacceptable | No A*24:10 beads in antibody panel. |
| 1461 | 65 | | Negative | A24 (1487) A2403 (1245) | Positive | DR9 (626) DR53 (3032) DPw4 (3053) | Acceptable | A*24:10,B*18:02,B*56:04,C*07:04 not included in Antibody panel |
| 2400 | 65 | 90 | Positive | A24 (6691) | Positive | | Unacceptable | I - 74%, II - 68% |
| 3224 | 65 | 96 | Positive | A24 (10319) | Positive | DR9 (3236) DR53 (13140) DQ7 (1886) DQ9 (2150) DP402 (9806) DP401 (2314) | Unacceptable | |
| 3753 | 65 | 92.1 | Positive | A24 (6075) | Positive | DR53 (10896) | Unacceptable | |
| 3966 | 65 | 95 | Positive | A24 (5088) | Positive | DR9 (2222) DR11 (3671) DR53 (10519) DPw4 (7739) | Unacceptable | A*24:10 is not in SAB panel. DR11 is previous transplantation. |
| 4661 | 65 | 89.5 | Positive | A24 (2128) B56 (47) A33 (25) B18 (55) Cw1 (66) Cw7 (99) | Positive | DR9 (75) DR12 (16) DR52 (30) DR53 (862) DQ7 (110) DQ9 (77) DPw4 (175) DPw5 (121) | Unacceptable | Ab against Epitope 82LR. Ab against Epitope 48Q6. |

Table 24. Individual Virtual crossmatch results for Serum #65 vs Donor #V1

Donor #V1 - HLA genotype: A*24:10-A*33:03-B*18:02-B*56:04-C*01:02:01G-C*07:04:01G/DRB1*09:01:02G-DRB1*12:02-DRB3*03:01-DRB4*01:01:01G-DQB1*03:01-DQB1*03:03-DPB1*04:01:01G-DPB1*05:01:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|-------------------------|---------------------------|--|-----------------|--|
| 5219 | 65 | | NP | No class I DSA | Positive | DR9 (653) DR53 (5809) DQ7 (742) DQ9 (655) DPw4 (1465) DPw5 (1328) | Unacceptable | HLA A*24:10, B*18:02 & C*07:04 present in the donor are not represented as allelic beads in the SAB testing panel. But HLA A24 antigen represented in the panel shows positivity with 3408 MFI |
| 8001 | 65 | 99 | Negative | No class I DSA | Positive | DR9 (1241) DR53 (11871) DQ3 (2003) DPw4 (2278) | Unacceptable | A*24:10, B*18:02, B*56:04, C*07:04 not included in LSAB panel |
| 8050 | 65 | 88 | Positive | A24 (4103) | Positive | DR9 (1743) DR53 (12760) | Unacceptable | |
| 8080 | 65 | 93 | Borderline | A24 (7738) | Positive | DR53 (10712) DQ9 (1814) DPw4 (1599) | Unacceptable | |
| 8083 | 65 | 97 | Negative | No class I DSA | Positive | DR53 (9827) DQ7 (1534) DQ9 (1827) DPw4 (2201) | Unacceptable | |
| 8096 | 65 | | Positive | A24 (494) Cw7 (299) | Positive | DR9 (3657) DR12 (6321) DR53 (7348) DPw4 (6586) | Unacceptable | |
| 8103 | 65 | | Borderline | A24 (1827) A2403 (1545) | Positive | DR53 (3339) DPw4 (3306) | Unacceptable | |

NP = not predicted

Table 25. Individual Virtual crossmatch results for Serum #65 vs Donor #V2

Donor #V2 - HLA genotype:

A*02:01-A*31:01-B*35:01:01G-B*44:02:01G-C*04:01:01G-C*05:01/DRB1*01:01-DRB1*15:01-DRB5*01:01-DQB1*05:01-DQB1*06:02-DPB1*02:01-DPB1*05:01:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|---|----------------------------|---|-----------------|--|
| 23 | 65 | | Positive | B44 (3392) Bw4 (4434) | Positive | DPw2 (6278) | Unacceptable | |
| 54 | 65 | 98 | Positive | B44 (4581) | Positive | DR1 (3129) DPw2 (10723) | Unacceptable | |
| 206 | 65 | 86 | Negative | No class I DSA | Negative | No DSA | Acceptable | |
| 230 | 65 | 94 | Borderline | B44 (3300) Bw4 (5500) | Borderline | DR1 (2520) DPw2 (9825) | Unacceptable | |
| 774 | 65 | 93 | Positive | B44 (2235) Bw4 (5346) | Positive | DR1 (2452) DPw2 (9368) | Unacceptable | |
| 792 | 65 | 100 | Positive | A2 (885) B44 (2122) B35 (573) | Positive | DR1 (2495) DPw2 (8286) | Unacceptable | |
| 836 | 65 | 99 | Positive | A2 (1383) B44 (1968) | Positive | DR1 (2589) DPw2 (8882) | Unacceptable | |
| | | | | A2 (1014) B44 (2424) B35 (572) Bw4 (6944) | | | | |
| 1160 | 65 | 93 | Positive | | Positive | DR1 (1300) DPw2 (8563) | Unacceptable | |
| 1461 | 65 | | Positive | B44 (716) | Positive | DPw2 (3045) | Acceptable | Low MFI antibody B*44:02 (612) |
| 3224 | 65 | 96 | Positive | A2 (1335) B44 (2641) Bw4 (7424) | Positive | DR1 (1917) DPw2 (8834) | Unacceptable | |
| 3753 | 65 | 92.1 | Negative | B44 (2556) | Positive | DR1 (1392) DPw2 (5432) | Unacceptable | |
| 3966 | 65 | 95 | Positive | B44 (2938) | Positive | DR11 (3671) DPA1*02 (6417) | Unacceptable | DR11 is previous transplantation |
| | | | | Cw4 (136) A2 (193) B44 (621) A31 (34) B35 (142) Cw5 (100) | | DR1 (75) DR15 (74) DR51 (1) DQ5 (94) DPw2 (799) DPw5 (121) DQ6 (39) | | |
| 4661 | 65 | 89.5 | Positive | | Positive | | Unacceptable | Ab against Epitope 82LR |
| 5219 | 65 | | Borderline | B44 (1035) | Positive | DPw2 (4828) DPw5 (1328) | Unacceptable | |
| 8001 | 65 | 99 | Positive | A2 (1098) B44 (2635) | Positive | DR1 (2540) DPw2 (9766) | Unacceptable | |
| 8050 | 65 | 88 | Negative | B44 (1923) | NP | DPw2 (7764) | Acceptable | Will Transplant with a single IVIG infusion. |
| 8080 | 65 | 93 | Negative | B44 (2496) | Borderline - Weak positive | DPw2 (7558) | Other- | Communication with the clinical program |
| 8083 | 65 | 97 | Negative | No class I DSA | Positive | DR1 (2360) DPw2 (8088) | Unacceptable | |
| 8096 | 65 | | Positive | B44 (531) | Positive | DR1 (4592) DR15 (3832) | Unacceptable | |
| 8103 | 65 | | Positive | Bw4 (1827) | Positive | DR53 (3339) DPw2 (3342) | Unacceptable | |

NP = not predicted

Table 26. Individual Virtual crossmatch results for Serum 65 vs Donor #V3

Donor #V3 - HLA genotype:

A*30:02-A*68:03-B*08:01-B*39:05-C*07:01:01G-C*07:02:01G/DRB1*03:01-DRB1*04:07:01G-DRB3*02:02:01G-DRB4*01:01:01G-DQB1*02:01-DQB1*03:02-DPB1*04:02:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|---|---------------------------|---|-----------------|--|
| 23 | 65 | | Negative | No class I DSA | Positive | DR4 (11580) DR53 (5951) DP402 (6837) | Unacceptable | |
| 54 | 65 | 98 | Negative | No class I DSA | Positive | DR4 (19425) DR53 (12999) DPw4 (10912) | Unacceptable | |
| 206 | 65 | 86 | Negative | No class I DSA | Positive | DR4 (17411) DR53 (14179) | Unacceptable | |
| 230 | 65 | 94 | Negative | No class I DSA | Positive | DR4 (19000) DR53 (14203) DP402 (6168) | Unacceptable | |
| 774 | 65 | 93 | Negative | No class I DSA | Positive | DR4 (17823) DR53 (13875) DPw4 (8458) | Unacceptable | |
| 792 | 65 | 100 | Negative | A68 (613) | Positive | DR4 (14641) DR53 (9344) DQ2 (730) DQ8 (1955) DP402 (8215) | Unacceptable | No DRB1*04:07 bead on SAB panel but other DR4 beads are positive |
| 836 | 65 | 99 | Positive | No class I DSA | Positive | DR4 (19771) DR53 (11970) DQ8 (2295) DP402 (9105) | Unacceptable | No DSA detected for the donor antigens typed and represented on the antibody panel |
| 1160 | 65 | 93 | Negative | A68 (515) | Positive | DR4 (19380) DR53 (12128) DQ2 (620) DQ8 (2653) DP402 (9472) | Unacceptable | very weak DSA against A68, however no A*68:03 bead in antibody panel |
| 1461 | 65 | | Negative | No class I DSA | Positive | DR4 (9622) DR53 (3032) DPw4 (3053) | Acceptable | A*30:02,A*68:03,B*39:05 not in Antibody panel |
| 3224 | 65 | 96 | Negative | No class I DSA | Positive | DR4 (17734) DR53 (13140) DQ8 (2554) DP402 (9805) | Unacceptable | |
| 3753 | 65 | 92.1 | Negative | No class I DSA | Positive | DR4 (17975) DR53 (10896) DP402 (5648) | Unacceptable | No HLA-Class I donor specific antibodies detected. |
| 3966 | 65 | 95 | Negative | No class I DSA | Positive | DR4 (14029) DR11 (3671) DR53 (10519) DPw4 (7739) | Unacceptable | No Class I DSA. DRB1*04:07 is not in SAB panel. |
| 4661 | 65 | 89.5 | Negative | A30 (33) A68 (127) B39 (28) B8 (38) Cw7 (99) | Positive | DR3 () DR4 (3464) DR52 (40) DR53 (862) DQ2 (76) DQ8 (108) DP402 (880) | Acceptable | Ab Ab against Epitope 96Y2, 48Q6, 57DED P |

Table 26. Individual Virtual crossmatch results for Serum 65 vs Donor #V3

Donor #V3 - HLA genotype:

A*30:02-A*68:03-B*08:01-B*39:05-C*07:01:01G-C*07:02:01G/DRB1*03:01-DRB1*04:07:01G-DRB3*02:02:01G-DRB4*01:01:01G-DQB1*02:01-DQB1*03:02-DPB1*04:02:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|-------------------|---------------------------|---|-----------------|---|
| 5219 | 65 | | Other - | No class I DSA | Positive | DR53 (5809) DQ8 (639) DPw4 (5161) | Unacceptable | HLA A*30:02, A*68:03, B*39:05 PRESENT IN THE DONOR NOT REPRESENTED AS ALLELIC BEAD IN THE SAB TESTING PANEL. HLA DRB1*04:07 PRESENT IN THE DONOR NOT REPRESENTED AS ALLELIC BEAD IN THE SAB TESTING PANEL. BUT HLA DR4 REPRESENTED IN THE PANEL SHOWS POSITIVITY WITH 15091 MFI |
| 8001 | 65 | 99 | Negative | No class I DSA | Positive | DR53 (11871) DQ8 (2367) DPw4 (9755) | Unacceptable | A*68:03, B*39:05, C*07:01 not included in LSAB panel. DRB1*04:07 not included in LSAB panel |
| 8050 | 65 | 88 | Negative | No class I DSA | Positive | DR4 (17157) DR53 (12760) DP402 (9142) | Unacceptable | |
| 8080 | 65 | 93 | Negative | No class I DSA | Positive | DR4 (12591) DR53 (10712) DQ8 (2256) DPw4 (8518) | Unacceptable | |
| 8083 | 65 | 97 | Negative | No class I DSA | Positive | DR53 (9827) DQ8 (2170) DPw4 (8046) | Unacceptable | |
| 8096 | 65 | | Positive | Cw7 (299) | Positive | DR4 (12917) DR53 (7348) DQ8 (12980) DPw4 (6586) | Unacceptable | |
| 8103 | 65 | | Negative | No class I DSA | Positive | DR4 (8575) DR53 (3339) DPw4 (3306) | Unacceptable | |

Table 27. Individual Virtual crossmatch results for Serum #65 vs Donor #V4

Donor #V4 - HLA genotype:

A*02:01-A*03:02-B*27:05:02G-B*51:01-C*01:02:01G-C*15:02:01G/DRB1*07:01-DRB1*16:01-DRB4*01:01:01G-DRB5*02:02:01G-DQB1*02:02-DQB1*05:02-DBP1*11-DBP1*15

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|--|---------------------------|--|-----------------|---|
| 23 | 65 | | Positive | B27 (3791) B51 (5565) Bw4 (4434) | Positive | DR53 (5950) | Unacceptable | |
| 54 | 65 | 98 | Positive | A2 (1451) B27 (4251) B51 (6629) | Positive | DR53 (12999) DP11 (2003) | Unacceptable | |
| 206 | 65 | 86 | Positive | B27 (3146) B51 (5151) | Positive | DR53 (14179) | Unacceptable | |
| 230 | 65 | 94 | Positive | B27 (3739) B51 (6007) | Positive | DR53 (14200) | Unacceptable | |
| 774 | 65 | 93 | Positive | B27 (2123) B51 (4174) Bw4 (5346) | Positive | DR53 (13875) | Unacceptable | B*27:05 DSA |
| 792 | 65 | 100 | Positive | A2 (885) B27 (3097) B51 (4652) | Positive | DR53 (9344) DQ2 (730) DQ7 (805) DP11 (1659) | Unacceptable | |
| 836 | 65 | 99 | Positive | A2 (1383) B27 (2845) B51 (4527) | Positive | DR53 (11970) DP11 (2119) | Unacceptable | |
| 1160 | 65 | 93 | Positive | A2 (1014) B27 (3559) B51 (5538) Bw4 (6944) | Positive | DR7 (825) DR53 (12128) | Unacceptable | Potential weak DSA against DPA1*01:03 DBP1*11:01 |
| 1461 | 65 | | Positive | B27 (611) B51 (681) | Positive | DR7 (576) DR53 (3032) | Acceptable | Low MFI antibody B*27:05 (611) and B*51:01 (681) |
| 3224 | 65 | 96 | Positive | A2 (1336) B27 (3851) B51 (6461) Bw4 (7424) | Positive | DR7 (1067) DR53 (13140) | Unacceptable | |
| 3753 | 65 | 92.1 | Positive | B27 (2900) B51 (4916) | Positive | DR53 (10896) | Unacceptable | |
| 3966 | 65 | 95 | Positive | B27 (2678) B51 (4642) | Positive | DR53 (10519) | Unacceptable | |
| 4661 | 65 | 89.5 | Positive | A2 (193) B27 (826) B51 (599) A3 (37) Cw1 (66) Cw15 (56) | Positive | DR7 (111) DR16 (28) DR51 () DR53 (862) DQ2 (76) DQ5 (56) DP11 (21) DP15 (42) | Unacceptable | Ab against Epitope 82LR. Ab against Epitope 48Q6 |
| 5219 | 65 | | Borderline | B27 (1433) B51 (844) | Positive | DR7 (528) DR53 (5809) | Unacceptable | HLA A*03:02 present in the donor is not represented in the Sab testing Panel. |
| 8001 | 65 | 99 | Positive | A2 (1098) B27 (3602) B51 (5431) | Positive | DR7 (960) DR53 (11871) | Unacceptable | A*03:02 not included in LSAB panel |
| 8050 | 65 | 88 | Positive | B27 (2323) B51 (4120) | Positive | DR53 (12760) | Unacceptable | |
| 8080 | 65 | 93 | Positive | B27 (3490) B51 (5385) | Positive | DR53 (10712) | Unacceptable | |
| 8083 | 65 | 97 | Positive | B27 (1364) B51 (2225) | Positive | DR53 (9827) DP11 (1889) | Unacceptable | |
| 8096 | 65 | | Positive | B27 (422) | Positive | DR53 (7348) DP11 (1931) | Unacceptable | |
| 8103 | 65 | | Positive | Bw4 (1827) | Positive | DR53 (3339) | Unacceptable | |

Table 28. Individual Virtual crossmatch results for Serum #66 vs Donor #V1

Donor #V1 - HLA genotype:

A*24:10-A*33:03-B*18:02-B*56:04-C*01:02:01G-C*07:04:01G/DRB1*09:01:02G-DRB1*12:02-DRB3*03:01-DRB4*01:01:01G-DQB1*03:01-DQB1*03:03-DPB1*04:01:01G-DPB1*05:01:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|---|---------------------------|--|-----------------|--|
| 23 | 66 | | Positive | B56 (7679) Cw1 (2438) Cw7 (9035) | Positive | No class II DSA | Unacceptable | |
| 54 | 66 | 88 | Positive | B56 (5989) Cw1 (2004) Cw7 (9815) | Negative | No class II DSA | Unacceptable | |
| 206 | 66 | 44 | Positive | B56 (10479) | Negative | No class II DSA | Unacceptable | |
| 230 | 66 | 73 | Positive | B56 (14508) Cw1 (4839) Cw7 (17543) | Negative | No class II DSA | Unacceptable | |
| 774 | 66 | 71 | Positive | B56 (10123) Cw7 (12785) | Negative | No class II DSA | Unacceptable | |
| 792 | 66 | 99 | Positive | B56 (8585) Cw1 (2609) Cw7 (9672) | Positive | DPw5 (680) | Unacceptable | No B*56:04 bead on SAB panel, but other B*56 bead is positive. Patient is DPB1*05 |
| 836 | 66 | 93 | Positive | B56 (9834) Cw1 (2980) Cw7 (9595) | Positive | No class II DSA | Unacceptable | No DSA detected for donor antigens typed and represented on the antibody panel. Only one result is reported for both T and B cell VXM. |
| 1160 | 66 | 47 | Positive | B56 (9030) Cw1 (1797) | Positive | No class II DSA | Unacceptable | |
| 1461 | 66 | | Negative | B56 (2100 Cw7 (2196) | Negative | No class II DSA | Acceptable | A*24:10,B*18:02,B*56:04,C*07:04 not in Antibody panel. |
| 2400 | 66 | 87 | Positive | B56 (10709) Cw1 (2793) Cw7 (13236) | Negative | No class II DSA | Unacceptable | I - 87%, II - 0% |
| 3224 | 66 | 89 | Positive | B56 (10015) Cw1 (2754) Cw7 (9618) | Positive | No class II DSA | Unacceptable | |
| 3753 | 66 | 92.7 | Positive | B56 (9054) Cw1 (4099) Cw7 (14299) | Positive | No class II DSA | Unacceptable | No HLA-Class II donor specific antibodies detected against this donor. |
| 3966 | 66 | 92 | Positive | B56 (10419) Cw1 (4895) | Negative | No class II DSA | Unacceptable | B*56:04 is not in SAB panel. |
| 4661 | 66 | 70.2 | Positive | A24 (159) B56 (2467) A33 (124) B18 (151) Cw1 (318) Cw7 (1794) | Positive | DR9 (52) DR12 (56) DR52 (78) DR53 (72) DQ7 (112) DQ9 (101) DPw4 (542) DPw5 (214) | Unacceptable | Ab against Epitope 65QIA, 193PL3 |

Table 28. Individual Virtual crossmatch results for Serum #66 vs Donor #V1

Donor #V1 - HLA genotype:

A*24:10-A*33:03-B*18:02-B*56:04-C*01:02:01G-C*07:04:01G/DRB1*09:01:02G-DRB1*12:02-DRB3*03:01-DRB4*01:01:01G-DQB1*03:01-DQB1*03:03-DPB1*04:01:01G-DPB1*05:01:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|------------------------------------|---------------------------|--------------------|-----------------|--|
| 5219 | 66 | | Other | No class I DSA | Negative | No class II DSA | - | HLA A*24:10, B*18:02 & C*07:04 present in the donor are not represented as allelic beads in the SAB testing panel. But HLA A24 antigen represented in the panel shows positivity with 3408 MFI |
| 8001 | 66 | 95 | Positive | Cw1 (3193) | Borderline | | Unacceptable | A*24:10, B*18:02, B*56:04, C*07:04 not included in LSAB panel |
| 8050 | 66 | 89 | Positive | B56 (10528) Cw1 (3491) Cw7 (14288) | Positive | No class II DSA | Unacceptable | Positive B cell prediction due to Class I |
| 8080 | 66 | 88 | Positive | B56 (8954) Cw1 (2002) Cw7 (6258) | Positive | | Unacceptable | |
| 8083 | 66 | 96 | Positive | Cw1 (4889) | Positive | DPw5 (1853) | Unacceptable | |
| 8096 | 66 | | Positive | B56 (3127) | Negative | No class II DSA | Unacceptable | |
| 8103 | 66 | | Borderline | B56 (1969) Cw7 (3129) | Negative | No class II DSA | Acceptable | CONFIRM WITH CELL-BASED CROSSMATCH. ANTIBODIES DETECTED B*56:01, C*07:01, C*07:02. |

Table 29. Individual Virtual crossmatch results for Serum #66 vs Donor #V2

Donor #V2 - HLA genotype:

A*02:01-A*31:01-B*35:01:01G-B*44:02:01G-C*04:01:01G-C*05:01/DRB1*01:01-DRB1*15:01-DRB5*01:01-DQB1*05:01-DQB1*06:02-DPB1*02:01-DPB1*05:01:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|--|---------------------------|---|-----------------|---|
| 23 | 66 | | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 54 | 66 | 88 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 206 | 66 | 44 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 230 | 66 | 73 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 774 | 66 | 71 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 792 | 66 | 99 | Negative | Cw5 (852) | Negative | DPw5 (680) | Acceptable | Patient is DPB1*05 |
| 836 | 66 | 93 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 1160 | 66 | 47 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 1461 | 66 | | Negative | No class I DSA | Negative | No Class II DSA | Acceptable | |
| 3224 | 66 | 89 | Negative | No class I DSA | Negative | No Class II DSA | Acceptable | |
| | | | | | | | | No HLA-Class I donor specific antibodies detected. No HLA-Class II donor specific antibodies detected against this donor. |
| 3753 | 66 | 92.7 | Negative | No class I DSA | Negative | No Class II DSA | Acceptable | |
| 3966 | 66 | 92 | Positive | Cw5 (1912) | Negative | No Class II DSA | Unacceptable | |
| 4661 | 66 | 70.2 | Negative | Cw4 (320) A2 (119) B44 (121) A31 (125) B35 (160) Cw5 (244) | Negative | DR1 (26) DR15 (150) DR51 (62) DQ5 (78) DPw2 (206) DPw5 (214) DQ6 (47) | Acceptable | |
| 5219 | 66 | | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 8001 | 66 | 95 | Borderline | Cw5 (1033) | Negative | No class II DSA | Acceptable | |
| 8050 | 66 | 89 | Negative | Cw5 (1009) | Negative | No class II DSA | Acceptable | Transplant with no IVIG |
| 8080 | 66 | 88 | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 8083 | 66 | 96 | Positive | Cw5 (1621) | Positive | DPw5 (1853) | Unacceptable | |
| 8096 | 66 | | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |
| 8103 | 66 | | Negative | No class I DSA | Negative | No class II DSA | Acceptable | |

Table 30. Individual Virtual crossmatch results for Serum #66 vs Donor #V3

Donor #V3 - HLA genotype:

A*30:02-A*68:03-B*08:01-B*39:05-C*07:01:01G-C*07:02:01G/DRB1*03:01-DRB1*04:07:01G-DRB3*02:02:01G-DRB4*01:01:01G-DQB1*02:01-DQB1*03:02-DPB1*04:02:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|---|---------------------------|--|-----------------|--|
| 23 | 66 | | Negative | Cw7 (9035) | Negative | No Class II DSA | Acceptable | |
| 54 | 66 | 88 | Positive | Cw7 (9815) | Negative | No Class II DSA | Unacceptable | |
| 206 | 66 | 44 | Negative | No class I DSA | Negative | No Class II DSA | Acceptable | |
| 230 | 66 | 73 | Positive | Cw7 (17544) | Negative | No Class II DSA | Unacceptable | |
| 774 | 66 | 71 | Positive | Cw7 (12785) | Negative | No Class II DSA | Unacceptable | |
| 792 | 66 | 99 | Positive | B8 (377) Cw7 (9672) | Positive | No Class II DSA | Unacceptable | |
| 836 | 66 | 93 | Positive | Cw7 (11797) | Positive | No class II DSA | Unacceptable | No DSA detected for donor antigens typed and represented on the antibody panel |
| 1160 | 66 | 47 | Negative | see comments | Negative | No class II DSA | Acceptable | Antibody against Cw7 was detected by single antigen bead assays (SAB), However is negative by phenotype beads. therefore it is false positive by SAB assays. |
| 1461 | 66 | | Negative | Cw7 (2196) | Negative | No class II DSA | Acceptable | A*30:02,A*68:03,B*39:05 not included in Antibody panel. DRB1*04:07 not included in Antibody Panel. |
| 3224 | 66 | 89 | Positive | Cw7 (9618) | Positive | No class II DSA | Unacceptable | Final crossmatch recommended to determine if both T and B cell positive. B cell positive due to Class I antibody. |
| 3753 | 66 | 92.7 | Positive | Cw7 (14299) | Positive | No class II DSA | Unacceptable | No HLA-Class II donor specific antibodies detected against this donor. |
| 3966 | 66 | 92 | Positive | Cw7 (12169) | Negative | No Class II DSA | Unacceptable | |
| 4661 | 66 | 70.2 | Positive | A30 (124) A68 (125) B39 (126) B8 (106) Cw7 (1794) | Positive | DR3 (55) DR4 (124) DR52 (76) DR53 (72) DQ2 (96) DQ8 (76) DP402 (354) | Unacceptable | Ab Ab against Epitope 193PL3 |
| 5219 | 66 | | Positive | Cw7 (3467) | Negative | No Class II DSA | Unacceptable | HLA A*30:02, A*68:03, B*39:05 PRESENT IN THE DONOR NOT REPRESENTED AS ALLELIC BEAD IN THE SAB TESTING PANEL. HLA DRB1*04:07 PRESENT IN THE DONOR NOT REPRESENTED AS ALLELIC BEAD IN THE SAB TESTING PANEL. |

Table 30. Individual Virtual crossmatch results for Serum #66 vs Donor #V3

Donor #V3 - HLA genotype:

A*30:02-A*68:03-B*08:01-B*39:05-C*07:01:01G-C*07:02:01G/DRB1*03:01-DRB1*04:07:01G-DRB3*02:02:01G-DRB4*01:01:01G-DQB1*02:01-DQB1*03:02-DPB1*04:02:01G

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|-------------------------|---------------------------|--------------------|-----------------|--|
| 8001 | 66 | 95 | Positive | Cw7 (12491) | Positive | No class II DSA | Unacceptable | A*68:03, B*39:05, C*07:01, DRB1*04:07 not included in LSAB panel |
| 8050 | 66 | 89 | Positive | Cw7 (14288) | Positive | No class II DSA | Unacceptable | Positive B cell prediction due to Class I |
| 8080 | 66 | 88 | Positive | Cw7 (18093) | Positive | No class II DSA | Unacceptable | |
| 8083 | 66 | 96 | Positive | B27 (10835) Cw7 (14719) | Negative | No class II DSA | Unacceptable | |
| 8096 | 66 | | Negative | No class I DSA | Negative | No class II DSA | Acceptable | No DSA detected |
| 8103 | 66 | | Positive | Cw7 (3129) | Negative | No class II DSA | Unacceptable | |

Table 31. Individual Virtual crossmatch results for Serum #66 vs Donor #V4

Donor #V4 - HLA genotype:

A*02:01-A*03:02-B*27:05:02G-B*51:01-C*01:02:01G-C*15:02:01G/DRB1*07:01-DRB1*16:01-DRB4*01:01:01G-DRB5*02:02:01G-DQB1*02:02-DQB1*05:02:DPB1*11:DPB1*15

| Center | Patient | CPRA | Virtual T Cell Prediction | Class I DSA (MFI) | Virtual B-cell prediction | Class II DSA (MFI) | Risk Assessment | Comments |
|--------|---------|------|---------------------------|--|---------------------------|--|-----------------|--|
| 23 | 66 | | Positive | B27 (7057) A3 (3699) Cw1 (2577) Cw15 (2749) | Positive | No class II DSA | Unacceptable | |
| 54 | 66 | 88 | Positive | B27 (5705) A3 (3045) Cw1 (2004) Cw15 (2462) | Negative | No class II DSA | Unacceptable | |
| 206 | 66 | 44 | Positive | B27 (9613) A3 (4983) | Negative | No class II DSA | Unacceptable | |
| 230 | 66 | 73 | Positive | B27 (12512) A3 (6880) Cw1 (4839) Cw15 (5648) | Negative | No class II DSA | Unacceptable | |
| 774 | 66 | 71 | Positive | B27 (10157) A3 (4788) | Negative | No class II DSA | Unacceptable | |
| 792 | 66 | 99 | Positive | B27 (7457) A3 (4000) Cw1 (2609) Cw15 (3051) | Positive | No class II DSA | Unacceptable | No A*03:02 bead on SAB panel but other A*03 bead is positive. |
| 836 | 66 | 93 | Positive | B27 (8358) A3 (4215) Cw1 (2980) Cw15 (3620) | Positive | No class II DSA | Unacceptable | No DSA detected for donor antigens typed and represented on the antibody panel |
| 1160 | 66 | 93 | Positive | B27 (7810) A3 (4155) Cw1 (1797) Cw15 (2167) | Positive | No class II DSA | Unacceptable | |
| 1461 | 66 | | Positive | B27 (2097) A3 (1258) | Negative | No class II DSA | Unacceptable | |
| 3224 | 66 | 89 | Positive | B27 (8836) A3 (4310) Cw1 (2753) Cw15 (3078) | Positive | No class II DSA | Unacceptable | likely B positive due to Class I antibody |
| 3753 | 66 | 92.7 | Positive | B27 (7876) A3 (5457) Cw1 (4099) Cw5 (4647) | Positive | No class II DSA | Unacceptable | No HLA-Class II donor specific antibodies detected against this donor. |
| 3966 | 66 | 92 | Positive | B27 (9263) A3 (4360) Cw1 (4945) | Negative | No class II DSA | Unacceptable | A*03:02 is not in SAB panel. |
| 4661 | 66 | 70.2 | Positive | A2 (119) B27 (2104) B51 (218) A3 (1310) Cw1 (318) Cw15 (220) | Positive | DR7 (48) DR16 (83) DR51 (61) DR53 (72) DQ2 (82) DQ5 (44) DP11 (140) DP15 (52) | Unacceptable | Ab against Epitope 161D, 65QIA |
| 5219 | 66 | | Positive | B27 (3389) | Negative | No class II DSA | Unacceptable | |
| 8001 | 66 | 95 | Positive | B27 (9302) Cw1 (3193) Cw15 (3669) | Positive | No class II DSA | Unacceptable | A*03:02 not included in LSAB panel |
| 8050 | 66 | 89 | Positive | B27 (9006) A3 (4386) Cw1 (3491) Cw15 (3442) | Positive | No class II DSA | Unacceptable | Positive B cell prediction due to Class I |
| 8080 | 66 | 88 | Positive | B27 (7563) A3 (2127) Cw1 (2002) Cw15 (2296) | Positive | No class II DSA | Unacceptable | |
| 8083 | 66 | 96 | Positive | B27 (10835) Cw1 (4889) Cw15 (4767) | Negative | No class II DSA | Unacceptable | |
| 8096 | 66 | | Positive | B27 (4301) A3 (3523) Cw15 (3945) | Negative | No class II DSA | Unacceptable | |
| 8103 | 66 | | Positive | B27 (1829) | Negative | No class II DSA | Unacceptable | |